var title_f6_36_6720="Rabies postexposure prophylaxis algorithm";
var content_f6_36_6720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Rabies postexposure prophylaxis algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 465px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In areas without an endemic, terrestrial strain of rabies (eg, dog, raccoon, skunk, fox, mongoose), contact local public health authorities for risk assessment.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alfred DeMaria Jr, MD and the Massachusetts Department of Public Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6720=[""].join("\n");
var outline_f6_36_6720=null;
var title_f6_36_6721="Spirapril: International drug information";
var content_f6_36_6721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Spirapril: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cardiopril (CH);",
"     </li>",
"     <li>",
"      Quadropril (AT, DE, HU);",
"     </li>",
"     <li>",
"      Renormax (ES, IT);",
"     </li>",
"     <li>",
"      Renpress (ES, NL, NO);",
"     </li>",
"     <li>",
"      Sandopril (AT, LU);",
"     </li>",
"     <li>",
"      Setrilan (IT);",
"     </li>",
"     <li>",
"      Spirapril Sanabo (AT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4089420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Angiotensin-Converting Enzyme (ACE) Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4089421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of mild to severe hypertension; treatment of left ventricular dysfunction after myocardial infarction",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4089423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 6 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4089424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 3 mg, 6 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10525 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-8641F3AC89-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6721=[""].join("\n");
var outline_f6_36_6721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369770\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089420\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089421\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089423\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821151\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089424\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10525\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10525|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_36_6722="Sites LV measurements";
var content_f6_36_6722=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sites for left ventricular measurements",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 282px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Measurements of left ventricular (LV) dimensions can be obtained from various views obtained from the 2 dimensional echocardiogram. Panel A is the apical four chamber view; M-mode tracings cannot be made from an apical view and thus measurements must be made directly from the two dimensional image. The dimensions of the right ventricle (RV) can also be obtained from this view. Panel B is the short axis precordial view; measurements from the short axis can be made interchangeably from either M-mode or two dimensional image. Panel C is the long axis precordial view; measurements of LV dimension can be made from either the two dimensional image or the M-mode tracing.",
"    <div class=\"footnotes\">",
"     Ao: aorta; LA: left atrium; RA: right atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6722=[""].join("\n");
var outline_f6_36_6722=null;
var title_f6_36_6723="PA pressure PDA Doppler echo-I";
var content_f6_36_6723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiography in a patient with patent ductus arteriosus and pulmonary arterial pressure calculation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pulmonary arterial pressure in a patient with a patent ductus arteriosus can be calculated using the continuous wave Doppler tracing. The beam of the continuous wave Doppler interrogation (arrow) is directed into the jet of continuous left to right flow in the parasternal short axis view. A peak velocity (V) of 4 m/sec is noted by continuous wave Doppler. The peak gradient across the ductus is (V x 4)",
"    <sup>",
"     2",
"    </sup>",
"    , or 64mmHg. This, subtracted from the cuff systolic pressure of 96 mmHg, is consistent with an estimated pulmonary arterial systolic pressure of 32 mmHg.",
"    <div class=\"footnotes\">",
"     AO: aorta, PA: main pulmonary artery.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Doyle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6723=[""].join("\n");
var outline_f6_36_6723=null;
var title_f6_36_6724="Fosfomycin: Drug information";
var content_f6_36_6724=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fosfomycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/32/2564?source=see_link\">",
"    see \"Fosfomycin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Monurol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Monurol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F174353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F174323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary tract infections, uncomplicated:",
"     </b>",
"     Oral: Females: Single dose of 3 g in 3-4 oz (90-120 mL) of water",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Complicated UTI (unlabeled):",
"     </b>",
"     Males: Oral: 3 g every 2-3 days for 3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostatitis (unlabeled):",
"     </b>",
"     Males: Oral: 3 g every 3 days for a total of 21 days (Shrestha, 2000)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F174324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5999403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monurol&reg;: 3 g/sachet (3s) [orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F174301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Always mix with cool water before ingesting; do not administer in its dry form. May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F174299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Single oral dose in the treatment of uncomplicated urinary tract infections in women due to susceptible strains of",
"     <i>",
"      E. coli",
"     </i>",
"     and",
"     <i>",
"      Enterococcus  faecalis",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F174349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple doses have been investigated for complicated urinary tract infections in men",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F174359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Monurol&reg; may be confused with Monopril&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F174351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (4% to 10%), pain (2%), dizziness (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine and metabolic: Dysmenorrhea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (9% to 10%), nausea (4% to 5%), abdominal pain (2%), dyspepsia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis (6% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (3%), weakness (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (5%), pharyngitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angioedema, anorexia, aplastic anemia, asthma (exacerbation), cholestatic jaundice, constipation, drowsiness, dysuria, ear disorder, fatigue, fever, flatulence, flu-like syndrome, hearing loss, hematuria, hepatic necrosis, insomnia, lymphadenopathy, menstrual disorder, migraine, myalgia, nervousness, optic neuritis, paresthesia, pruritus, SGPT increased, skin disorder, somnolence, stools abnormal, toxic megacolon, vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5996052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fosfomycin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5996053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &le;12 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5996050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fosfomycin crosses the placenta. Because teratogenicity was not observed in animals, fosfomycin is classified pregnancy category B. There have been several human studies using single dose therapy with fosfomycin for the treatment of asymptomatic bacteriuria during pregnancy. In these studies, fosfomycin was well-tolerated and adverse fetal effects were not observed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F174328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excreted into breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7277079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although the manufacturer does not recommend using fosfomycin while breast-feeding, very small amounts appear to enter human milk. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5996126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4370642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Monurol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 g (3): $166.22",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F174296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of urinary tract infection; urine culture plus sensitivity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F174308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Folsmycin (TW);",
"     </li>",
"     <li>",
"      Fosfocil (DO, GT, HN, PA, SV);",
"     </li>",
"     <li>",
"      Fosfocina (EC);",
"     </li>",
"     <li>",
"      Fosfomin (TH);",
"     </li>",
"     <li>",
"      Fosfurol (PY, UY);",
"     </li>",
"     <li>",
"      Fosmicin-S (JP);",
"     </li>",
"     <li>",
"      Fosmidex (ID);",
"     </li>",
"     <li>",
"      Monural (BG, HU, PL, RU);",
"     </li>",
"     <li>",
"      Monuril (BR, CH, CO, DE, FR, ID, IE, LU, PT);",
"     </li>",
"     <li>",
"      Monurol (AR, AT, BE, CL, CN, ES, FI, GR, HK, IL, IT, KP, MX, MY, NL, PE, PH, PK, SE, SG, TH, TR, TW);",
"     </li>",
"     <li>",
"      Novellmycin (ID);",
"     </li>",
"     <li>",
"      Uridoz (FR);",
"     </li>",
"     <li>",
"      Veramina (AR);",
"     </li>",
"     <li>",
"      Veramina[inj.] (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F174287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a phosphoric acid derivative, fosfomycin inhibits bacterial wall synthesis (bactericidal) by inactivating the enzyme, pyruvyl transferase, which is critical in the synthesis of cell walls by bacteria",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F174303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapidly absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 90-180 L; high concentrations in urine; well into other tissues; crosses maximally into CSF with inflamed meninges",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Fasting: 37%; With food: 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 4-8 hours; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;54 mL/minute: 50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2 hours; within 4 hours with high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (38% as unchanged drug); high urinary levels (100 mcg/mL) persist for &gt;48 hours; feces (18% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Patel SS, Balfour JA, and Bryson HM, &ldquo;Fosfomycin Tromethamine. A Review of Its Antibacterial Activity, Pharmacokinetic Properties, and Therapeutic Efficacy as a Single-Dose Oral Treatment for Acute Uncomplicated Lower Urinary Tract Infections,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1997, 53(4):637-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/36/6724/abstract-text/9098664/pubmed\" id=\"9098664\" target=\"_blank\">",
"        9098664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shrestha N, Amuh D, Goldman MP, et al, &ldquo;Treatment of a Complicated Vancomycin-Resistant Enterococcal Urinary Tract Infection With Fosfomycin,&rdquo;",
"      <i>",
"       Infectious Diseases in Clinical Practice",
"      </i>",
"      , 2000, 9:368-71.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8477 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6724=[""].join("\n");
var outline_f6_36_6724=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174319\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174320\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174353\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174323\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174324\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896290\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5999403\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174298\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174284\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174301\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174299\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174349\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174359\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174351\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5996052\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5996053\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299365\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174292\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174294\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5996050\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174328\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7277079\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5996126\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370642\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174296\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174308\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174287\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174303\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8477\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8477|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/32/2564?source=related_link\">",
"      Fosfomycin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_36_6725="Dalfampridine (fampridine): Drug information";
var content_f6_36_6725=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dalfampridine (fampridine): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/25/19860?source=see_link\">",
"    see \"Dalfampridine (fampridine): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14694100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Risk of Seizures with Dalfampridine Therapy",
"     </span>",
"     <span class=\"collapsible-date\">",
"      July 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals about the risk of seizure in patients with multiple sclerosis initiated on dalfampridine (Ampyra&trade;). The FDA recently evaluated postmarketing reports of adverse events and noted an elevated risk of seizure; the majority of seizures occurred within days to weeks after initiation of the recommended dose in patients with no history of seizures. The FDA is also updating the Ampyra&trade; labeling to clarify recommendations that renal function be assessed in patients before starting the drug and monitored at least annually during treatment. In patients who miss a dose, double or extra doses should not be administered as that may increase seizure risk.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, see",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm312846.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm312846.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9831169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ampyra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13922165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fampyra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9832440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Potassium Channel Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9948903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Multiple sclerosis:",
"     </b>",
"     Oral: 10 mg every 12 hours (maximum daily dose: 20 mg); no additional benefit seen with doses &gt;20 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Missed doses:",
"     </i>",
"     Do not administer double or extra doses if a dose is missed.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9948904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9948905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Creatinine clearance is estimated with Cockcroft-Gault formula.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Mild renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     51-80 mL/minute): No dosage adjustment recommended by the manufacturer; however, use with extreme caution as risk of seizure may be increased secondary to reduced clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Moderate-to-severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute): Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Mild-to-severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;80 mL/minute): Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13922166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required; drug undergoes minimal metabolism and is primarily excreted unchanged in the urine.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9948912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ampyra&trade;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13925479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fampyra&trade;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F16317978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9948871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199168.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM199168.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9948908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food. Do not chew, crush, dissolve, or divide tablet.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9832441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment to improve walking in patients with multiple sclerosis (MS)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9832437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ampyra&trade; may be confused with anakinra",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dalfampridine may be confused with delavirdine, desipramine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dalfampridine (U.S.) and fampridine (Canada) are different generic names for the same chemical entity (4-aminopyridine)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9948886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Genitourinary: Urinary tract infection (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Insomnia (9%), dizziness (7%), headache (7%), multiple sclerosis relapse (4%), seizures (up to 4%; dose-dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (7%), constipation (3%), dyspepsia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (7%), back pain (5%), balance disorder (5%), paresthesia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (4%), pharyngolaryngeal pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Allergic reaction, anaphylaxis, confusion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9948876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dalfampridine, 4-aminopyridine, or any component of the formulation; history of seizure; moderate or severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Mild, moderate, severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;80 mL/minute); concomitant use with compounded 4-aminopyridine or other forms of fampridine; concomitant use with drugs that inhibit organic cation transporter 2 (OCT2), such as cimetidine or quinidine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9948877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse reactions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anaphylaxis: May cause anaphylaxis or severe allergic reactions; symptoms have included respiratory compromise, urticaria, and angioedema (throat and tongue). Discontinue immediately and administer appropriate medical care if a severe allergic reaction occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Seizures: Associated with a dose-dependent risk of seizure; seizures may occur within days to weeks after treatment initiation and have been reported more frequently in patients with no history of seizures. Discontinue use and do not reinitiate therapy if seizure occurs during treatment. Use is contraindicated in patients with a history of seizures. Assess risk of seizure prior to treatment initiation; use caution or avoid in patients who may have a lower seizure threshold due to predisposing factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Urinary tract infection: Urinary tract infections were reported more frequently in patients receiving dalfampridine (compared to placebo),",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use in renal impairment is associated with an increased risk of seizure and other adverse events, primarily neurologic effects, due to increased serum concentrations; elimination is predominately via the kidneys as unchanged drug. U.S. labeling contraindicates use in moderate-to-severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute). Canadian labeling contraindicates use in mild, moderate, and severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;80 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; 4-aminopyridine formulations: Sustained release products available in the U.S. (dalfampridine) or in Canada (fampridine) should not be administered with other 4-aminopyridine formulations (eg, compounded immediate release fampridine).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Name confusion: The chemical entity of 4-aminopyridine is referred to with a generic name of dalfampridine in the U.S. and with a generic name of fampridine in Canada.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2E1 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10073097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Dalfampridine. Management: Recommendations differ significantly between international labelings in regards to the concomitant use of dalfampridine (referred to as fampridine in Canada) and cimetidine. Consult appropriate product labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Dalfampridine may increase the serum concentration of MetFORMIN. MetFORMIN may increase the serum concentration of Dalfampridine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Dalfampridine. Management: Recommendations differ significantly between international labelings in regards to the concomitant use of dalfampridine (referred to as fampridine in Canada) and quinidine. Consult appropriate product labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9948872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9948873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies, including decreased growth and death.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9948874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9948875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if dalfampridine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue dalfampridine or to discontinue breast-feeding is not recommended should take into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9948907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Ampyra Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (60): $1735.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9948910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function (baseline and at least annually thereafter); EEG; walking ability",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14190113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fampyra (AU, CZ, DE, DK, EE, GB, IE, NO, NZ, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9948891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nonspecific potassium channel blocker which improves conduction in focally demyelinated axons by delaying repolarization and prolonging the duration of action potentials. Enhanced neuronal conduction is thought to strengthen skeletal muscle fiber twitch activity, thereby, improving peripheral motor neurologic function.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9948893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Negligible; predominantly unbound to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Limited metabolism;",
"     <i>",
"      in vitro",
"     </i>",
"     data suggests hepatic metabolism to 3-hydroxy-4-aminopyridine occurs primarily via CYP2E1; further conjugated to 3-hydroxy-4-aminopyridine sulfate; metabolites are inactive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 96% (relative to aqueous solution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 5.2-6.5 hours; prolonged in severe renal impairment (~3 times longer)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (96%; 90% of total dose as unchanged drug); feces (0.5%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Feret B, &ldquo;Fampridine-SR: A Potassium-Channel Blocker for the Improvement of Walking Ability in Patients With MS,&rdquo;",
"      <i>",
"       Formulary",
"      </i>",
"      , 2009, 44:293-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goodman AD, Brown TR, Edwards KR, et al, &ldquo;A Phase 3 Trial of Extended Release Oral Dalfampridine in Multiple Sclerosis,&rdquo;",
"      <i>",
"       Ann Neurol",
"      </i>",
"      , 2010, 68(4):494-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/36/6725/abstract-text/20976768/pubmed\" id=\"20976768\" target=\"_blank\">",
"        20976768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goodman AD, Brown TR, Krupp LB, et al, &ldquo;Sustained-Release Oral Fampridine in Multiple Sclerosis: A Randomised, Double-Blind, Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 373(9665):732-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/36/6725/abstract-text/19249634/pubmed\" id=\"19249634\" target=\"_blank\">",
"        19249634",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Korenke AR, Rivey MP, and Allington DR. &ldquo;Sustained-Release Fampridine for Symptomatic Treatment of Multiple Sclerosis,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(10):1458-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/36/6725/abstract-text/18780812/pubmed\" id=\"18780812\" target=\"_blank\">",
"        18780812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9095 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6725=[""].join("\n");
var outline_f6_36_6725=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14694100\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9831169\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13922165\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9832440\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948903\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948904\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948905\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13922166\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948912\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13925479\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317978\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948871\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948908\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9832441\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9832437\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948886\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948876\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948877\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299120\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10073097\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948872\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948873\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948874\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948875\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948907\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322795\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948910\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190113\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948891\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9948893\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9095\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9095|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/25/19860?source=related_link\">",
"      Dalfampridine (fampridine): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_36_6726="Large ruptured abdominal aortic aneurysm";
var content_f6_36_6726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Large ruptured abdominal aortic aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A ruptured 9.6 cm infrarenal abdominal aneurysm of a 70-year-old male with pain and hypotension is shown in the axial CT image. Blood dissects into the left-sided posterior pararenal space, perirenal space, and into Gerota's fascia (arrow in A). The site of rupture (arrow in B) is noted more inferiorly.",
"    <div class=\"footnotes\">",
"     CT: Computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6726=[""].join("\n");
var outline_f6_36_6726=null;
var title_f6_36_6727="Nutritional composition of human milk for full-term infants";
var content_f6_36_6727=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nutritional composition of human milk for full-term infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/36/6727/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/36/6727/contributors\">",
"     Richard J Schanler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/36/6727/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/36/6727/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/36/6727/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/36/6727/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/36/6727/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human milk is recommended as the exclusive nutrient source for feeding term infants for the first six months of life and should be continued with the addition of solid foods after six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/1\">",
"     1",
"    </a>",
"    ]. Breastfeeding for all infants is strongly supported by both governmental and medical professional organizations because of its acknowledged benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The composition of human milk is both complex, containing multiple nutrients, and remarkable for its variability. As an example, the concentration of some nutrients may differ between women, and according to duration of lactation or time of day, whereas the concentration of other nutrients is relatively constant [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/4\">",
"     4",
"    </a>",
"    ]. The composition of human milk is ideally suited to the full-term infant. The ability to vary the content permits nutrient composition to be adapted to meet the ongoing needs of the infant. In addition, the lack of monotony in the diet may potentially stimulate sensory development and permit better acceptance of new flavors and foods [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6519?source=see_link\">",
"     \"Physiology of lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The individual components of human milk and the ways in which they contribute to meet the nutritional needs of full-term infants will be discussed here. Breastfeeding in the perinatal period, complications of breastfeeding, and benefits of breastfeeding are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=see_link\">",
"     \"Breastfeeding: Parental education and support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=see_link\">",
"     \"Common problems of breastfeeding and weaning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50899589\">",
"    <span class=\"h1\">",
"     ENERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is some variability, the energy content of human milk is about 20",
"    <span class=\"nowrap\">",
"     kcal/oz",
"    </span>",
"    (0.67",
"    <span class=\"nowrap\">",
"     kcal/mL).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NITROGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    nitrogen content of human milk is divided into protein and nonprotein nitrogen-containing compounds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protein content for human milk is highest at birth and is approximately 2.3",
"    <span class=\"nowrap\">",
"     gm/dL",
"    </span>",
"    in milk from mothers of full-term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/6\">",
"     6",
"    </a>",
"    ]. The protein concentration declines over the next two to four weeks to a steady level of approximately 1.8 g of protein per dL [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This protein content provides about eight percent of the caloric needs of full-term infants and ensures an adequate protein status of the breastfed infant throughout the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Whey and casein",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two fractions of protein defined by their solubility in acid: whey and casein. Approximately 70 percent of the proteins in human milk are in the soluble whey fraction and 30 percent in the insoluble casein fraction. In contrast, bovine milk protein contains 18 percent whey and 82 percent casein [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The high proportion of whey protein in human milk is beneficial for infants for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to casein, whey is more easily digested and is associated with more rapid gastric emptying [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The whey protein fraction provides lower concentrations of potentially deleterious amino acids, phenylalanine, tyrosine, and methionine. In high levels, these amino acids may interfere with brain development. Infants fed human milk have lower levels of these amino acids than infants fed bovine milk [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. In addition, human milk has higher levels of cystine (needed to synthesize the antioxidant glutathione) and taurine (needed for bile conjugation and brain development) than bovine milk [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/12-14\">",
"       12-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The major human whey protein is lactalbumin. In bovine milk, the major whey protein is lactoglobulin, which may contribute to milk protein allergy and colic [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/9,15,16\">",
"       9,15,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"       \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29640?source=see_link\">",
"       \"Milk allergy: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10680?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical features and etiology of colic\", section on 'Cow's milk protein'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lactoferrin, lysozyme, and secretory immunoglobulin A are specific human whey proteins that improve host defense [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/17-19\">",
"       17-19",
"      </a>",
"      ]. Bovine milk only has trace amounts of these proteins. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link&amp;anchor=H2#H2\">",
"       \"Infant benefits of breastfeeding\", section on 'Direct benefits'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Non-protein nitrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;In human milk, approximately 20 percent of the total nitrogen is in the form of nonprotein nitrogen-containing compounds such as nucleotides, free amino acids, and urea. In contrast, formula has &lt;5 percent nonprotein nitrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/9,20\">",
"     9,20",
"    </a>",
"    ]. There is debate as to how much these nonprotein nitrogen-containing compounds contribute to nitrogen utilization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The rate of absorption of nonprotein nitrogen, determined by stable isotope methods, has been estimated at 13 to 43 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Nucleotides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleotides represent 2 to 5 percent of the nonprotein nitrogen in human milk and are lacking in bovine milk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/23\">",
"     23",
"    </a>",
"    ]. Nucleotides are important for gastrointestinal, immune, and metabolic functions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. As an example, nucleotides are important for the normal development, maturation, and repair of the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, the growth of nonpathogenic bifidobacteria in stool is enhanced by exogenous nucleotides [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/23\">",
"     23",
"    </a>",
"    ]. Although nucleotides can be synthesized endogenously, the rapid growth of infants creates a demand for nucleotides that exceeds their endogenous supply [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LIPID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid (fat) represents approximately 50 percent of the calories in human milk. The lipid and energy contents of human milk increase during lactation. This was illustrated in a study that compared human milk samples of mothers who had breast fed for &gt;1 year to those from mothers who had breast fed for two to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/27\">",
"     27",
"    </a>",
"    ]. Milk from mothers who had lactated longer provided more energy content (880",
"    <span class=\"nowrap\">",
"     kcal/L",
"    </span>",
"    versus 741",
"    <span class=\"nowrap\">",
"     kcal/L,",
"    </span>",
"    respectively) and had more fat content estimated by creamatocrit measurement (10.7 versus 7.4 percent). (Creamatocrit is determined by centrifugation of 75 microL milk samples within glass capillary tubes. The measurement of fat is the percentage of fat to the total length of the milk.)",
"   </p>",
"   <p>",
"    Human milk facilitates lipid digestion and absorption by its organization of lipid into milk fat globule triglycerides [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/28\">",
"     28",
"    </a>",
"    ]. These globules are digested by bile salt-stimulated gastric lipase [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Human milk is unique in its content of very long-chain fatty acids such as arachidonic acid and docosahexaenoic acid, derivatives of the essential fatty acids, linoleic and linolenic acids. Arachidonic and docosahexaenoic acids have been associated with improved cognition, growth, and vision [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link&amp;anchor=H23#H23\">",
"     \"Infant benefits of breastfeeding\", section on 'Neurodevelopmental outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fatty acids in human milk are distributed on the triglyceride molecule and consist of a high proportion of long-chain fatty acids: palmitic, oleic, and the essential fatty acids, linoleic, and linolenic. The triglyceride structure is designed for enhanced lipid absorption with esterification of palmitic acid, the major fatty acid. This permits lipase to hydrolyze palmitic acid into two monoglycerides, which are better absorbed than the free palmitic acid. In addition to enhanced lipid absorption, mineral absorption is improved since free palmitic acid is not available to bind minerals. The enhanced absorption of lipid and minerals from human milk is diminished if human milk is pasteurized because lipase is heat labile [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To match the overall lipid absorption from human milk, formula has a greater quantity of passively absorbed medium chain-length fatty acids (MCFA) than human milk. This supplementation of MCFA decreases the overall content of long-chain fatty acids in formula compared to human milk.",
"   </p>",
"   <p>",
"    Of the macronutrients in human milk, lipid is the most variable in concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/34\">",
"     34",
"    </a>",
"    ]. The milk lipid content rises throughout lactation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/27\">",
"     27",
"    </a>",
"    ], varies over the course of one day, increases within feeds, and varies from mother to mother [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/4\">",
"     4",
"    </a>",
"    ] and perhaps with the degree of breast emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/35\">",
"     35",
"    </a>",
"    ]. The total lipid content of human milk is not affected by maternal diet, although it may be correlated directly with maternal body fat stores [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Despite the variability among women, human milk lipid content is adequate for the nutritional needs of the infant throughout lactation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CARBOHYDRATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human milk carbohydrate is comprised principally of lactose, with a small proportion consisting of oligosaccharides. Studies in term infants demonstrate unabsorbed lactose in the feces of breast-fed infants, which is assumed to be a normal consequence of breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. A softer stool consistency, nonpathogenic bacterial fecal flora, and improved absorption of minerals have been attributed to the lactose in human milk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/40\">",
"     40",
"    </a>",
"    ]. Oligosaccharides, found in carbohydrate polymers and glycoproteins, are important in the host defense of the infant as their structures mimic specific bacterial antigen receptors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link&amp;anchor=H4#H4\">",
"     \"Infant benefits of breastfeeding\", section on 'Anti-microbial components'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MINERAL AND TRACE ELEMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concentrations of calcium and phosphorus in human milk are relatively constant through lactation but are significantly lower than in formula. Despite lower mineral concentration and intake, bone mineral accretion and status of breastfed infants is similar to that of infants fed formula due to enhanced absorption (bioavailability) during the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In human milk, minerals are bound to digestible proteins and are also present in complexed and ionized states making them more readily bioavailable than in bovine milk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/43\">",
"     43",
"    </a>",
"    ]. In one study, follow-up at eight years of age showed that children who were breast-fed compared to those not breast-fed had significantly greater bone mass, and the effect was greater in those who had breast-fed for &gt;3 months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although concentrations of iron, zinc, and copper decline during lactation, the needs for these nutrients are usually adequately met through the first six months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beyond six months of age, iron and other micronutrient-containing complementary foods should be introduced to prevent deficiencies in full-term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6727/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     VITAMINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal vitamin status effects the content of vitamins in human milk. For example, maternal vitamin deficiency can result in low vitamin concentrations in breast milk, which increase in response to maternal dietary supplementation.",
"   </p>",
"   <p>",
"    Potential vitamin deficiencies in breast-fed infants include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mothers who are on a vegan diet may be deficient in the water-soluble vitamin B12 resulting in low breast milk levels. These mothers should receive vitamin B12 supplementation or should eat foods fortified with vitamin B12. Commonly used B12-fortified foods include certain brands of nutritional yeasts, most ready-to-eat cereals, many meat analogs, and some milk alternatives.",
"     </li>",
"     <li>",
"      Vitamin K deficiency is common in the newborn infant. This is due to the low vitamin K content of breast milk, inadequate production of vitamin K by an immature liver, absence of the bacterial flora that produce vitamin K, and poor placental transfer of vitamin K. In breast-fed infants, the plasma concentrations of all vitamin K dependent factors are about 20 percent of the adult values. Therefore, prophylactic administration of vitamin K1 oxide (phytonadione, 1 mg IM) is given to newborns shortly after birth to prevent vitamin K hemorrhagic disease of the newborn. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of vitamin K\", section on 'Vitamin K deficient bleeding in the newborn'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of the routine management of the healthy newborn infant\", section on 'Vitamin K'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The content of vitamin D in human milk is low. Vitamin D supplementation should be provided to exclusively breastfed infants and non-breastfed infants who do not ingest at an adequate amount of vitamin D-fortified milk daily. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H723639#H723639\">",
"       \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Vitamin D supplementation for infants'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"       \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"       \"Patient information: Common breastfeeding problems (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=see_link\">",
"       \"Patient information: Breast pumps (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"       \"Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human milk is recommended as the exclusive nutrient source for infants during the first six months of life. Human milk should be continued along with complementary foods through 12 months of age, and subsequent breastfeeding can continue depending on the mutual agreement between mother and infant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Human milk protein, lipid, carbohydrate, vitamins, mineral and trace element content provide the necessary energy and nutrient requirements of the full term infant. Vitamin D supplementation, however, is recommended at discharge from the birth hospital at a dose of 400 int.",
"    <span class=\"nowrap\">",
"     units/day.",
"    </span>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/1\">",
"      Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2012; 129:e827.",
"     </a>",
"    </li>",
"    <li>",
"     Department of Health and Human Services, Office on Women's Health. Breastfeeding: HHS Blueprint for Action on Breastfeeding. US Department of Health and Human Services, Washington, DC 2000.",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Breastfeeding: maternal and infant aspects. ACOG Educational Bulletin 258, American College of Obstetricians and Gynecologists, Washington DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/4\">",
"      Neville MC, Keller RP, Seacat J, et al. Studies on human lactation. I. Within-feed and between-breast variation in selected components of human milk. Am J Clin Nutr 1984; 40:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/5\">",
"      Mennella JA. Mother's milk: a medium for early flavor experiences. J Hum Lact 1995; 11:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/6\">",
"      Gross SJ, David RJ, Bauman L, Tomarelli RM. Nutritional composition of milk produced by mothers delivering preterm. J Pediatr 1980; 96:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/7\">",
"      Schanler RJ, Oh W. Composition of breast milk obtained from mothers of premature infants as compared to breast milk obtained from donors. J Pediatr 1980; 96:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/8\">",
"      Dewey KG, Cohen RJ, Rivera LL, et al. Do exclusively breast-fed infants require extra protein? Pediatr Res 1996; 39:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/9\">",
"      Hambraeus L. Proprietary milk versus human breast milk in infant feeding. A critical appraisal from the nutritional point of view. Pediatr Clin North Am 1977; 24:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/10\">",
"      Billeaud C, Guillet J, Sandler B. Gastric emptying in infants with or without gastro-oesophageal reflux according to the type of milk. Eur J Clin Nutr 1990; 44:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/11\">",
"      Rassin DK, Gaull GE, R&auml;ih&auml; NC, Heinonen K. Milk protein quantity and quality in low-birth-weight infants. IV. Effects on tyrosine and phenylalanine in plasma and urine. J Pediatr 1977; 90:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/12\">",
"      Gaull GE, Rassin DK, R&auml;ih&auml; NC, Heinonen K. Milk protein quantity and quality in low-birth-weight infants. III. Effects on sulfur amino acids in plasma and urine. J Pediatr 1977; 90:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/13\">",
"      J&auml;rvenp&auml;&auml; AL, Rassin DK, R&auml;ih&auml; NC, Gaull GE. Milk protein quantity and quality in the term infant. II. Effects on acidic and neutral amino acids. Pediatrics 1982; 70:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/14\">",
"      J&auml;rvenp&auml;&auml; AL, R&auml;ih&auml; NC, Rassin DK, Gaull GE. Feeding the low-birth-weight infant: I. Taurine and cholesterol supplementation of formula does not affect growth and metabolism. Pediatrics 1983; 71:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/15\">",
"      Jakobsson I, Lindberg T, Benediktsson B, Hansson BG. Dietary bovine beta-lactoglobulin is transferred to human milk. Acta Paediatr Scand 1985; 74:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/16\">",
"      Savilahti E, Kuitunen M. Allergenicity of cow milk proteins. J Pediatr 1992; 121:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/17\">",
"      Goldman AS, Chheda S, Keeney SE, et al. Immunologic protection of the premature newborn by human milk. Semin Perinatol 1994; 18:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/18\">",
"      L&ouml;nnerdal B. Biochemistry and physiological function of human milk proteins. Am J Clin Nutr 1985; 42:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/19\">",
"      Hanson LA, Ahlstedt S, Andersson B, et al. Protective factors in milk and the development of the immune system. Pediatrics 1985; 75:172.",
"     </a>",
"    </li>",
"    <li>",
"     Carlson SE. Human milk nonprotein nitrogen: occurrence and possible functions. In: Advances In Pediatrics, Barness LA (Ed), Year Book Medical Publishers, Inc., Chicago 1985. p.43.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/21\">",
"      Heine W, Tiess M, Wutzke KD. 15N tracer investigations of the physiological availability of urea nitrogen in mother's milk. Acta Paediatr Scand 1986; 75:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/22\">",
"      Fomon SJ, Bier DM, Matthews DE, et al. Bioavailability of dietary urea nitrogen in the breast-fed infant. J Pediatr 1988; 113:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/23\">",
"      Uauy R, Quan R, Gil A. Role of nucleotides in intestinal development and repair: implications for infant nutrition. J Nutr 1994; 124:1436S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/24\">",
"      Carver JD, Walker WA. The role of nucleotides in human nutrition. Nutr Biochem 1995; 6:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/25\">",
"      Schaller JP, Kuchan MJ, Thomas DL, et al. Effect of dietary ribonucleotides on infant immune status. Part 1: Humoral responses. Pediatr Res 2004; 56:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/26\">",
"      Buck RH, Thomas DL, Winship TR, et al. Effect of dietary ribonucleotides on infant immune status. Part 2: Immune cell development. Pediatr Res 2004; 56:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/27\">",
"      Mandel D, Lubetzky R, Dollberg S, et al. Fat and energy contents of expressed human breast milk in prolonged lactation. Pediatrics 2005; 116:e432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/28\">",
"      Jensen RG. The lipids in human milk. Prog Lipid Res 1996; 35:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/29\">",
"      Hernell O, Bl&auml;ckberg L. Human milk bile salt-stimulated lipase: functional and molecular aspects. J Pediatr 1994; 125:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/30\">",
"      Jensen RG, Jensen GL. Specialty lipids for infant nutrition. I. Milks and formulas. J Pediatr Gastroenterol Nutr 1992; 15:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/31\">",
"      Sauerwald TU, Demmelmair H, Koletzko B. Polyunsaturated fatty acid supply with human milk. Lipids 2001; 36:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/32\">",
"      Uauy R, Hoffman DR, Peirano P, et al. Essential fatty acids in visual and brain development. Lipids 2001; 36:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/33\">",
"      Jensen RG, Hagerty MM, McMahon KE. Lipids of human milk and infant formulas: a review. Am J Clin Nutr 1978; 31:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/34\">",
"      Butte NF, Garza C, Smith EO. Variability of macronutrient concentrations in human milk. Eur J Clin Nutr 1988; 42:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/35\">",
"      Daly SE, Di Rosso A, Owens RA, Hartmann PE. Degree of breast emptying explains changes in the fat content, but not fatty acid composition, of human milk. Exp Physiol 1993; 78:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/36\">",
"      Nommsen LA, Lovelady CA, Heinig MJ, et al. Determinants of energy, protein, lipid, and lactose concentrations in human milk during the first 12 mo of lactation: the DARLING Study. Am J Clin Nutr 1991; 53:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/37\">",
"      Butte NF, Garza C, Stuff JE, et al. Effect of maternal diet and body composition on lactational performance. Am J Clin Nutr 1984; 39:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/38\">",
"      Whyte RK, Homer R, Pennock CA. Faecal excretion of oligosaccharides and other carbohydrates in normal neonates. Arch Dis Child 1978; 53:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/39\">",
"      MacLean WC Jr, Fink BB. Lactose malabsorption by premature infants: magnitude and clinical significance. J Pediatr 1980; 97:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/40\">",
"      Ziegler EE, Fomon SJ. Lactose enhances mineral absorption in infancy. J Pediatr Gastroenterol Nutr 1983; 2:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/41\">",
"      Venkataraman PS, Luhar H, Neylan MJ. Bone mineral metabolism in full-term infants fed human milk, cow milk-based, and soy-based formulas. Am J Dis Child 1992; 146:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/42\">",
"      Greer FR, Searcy JE, Levin RS, et al. Bone mineral content and serum 25-hydroxyvitamin D concentrations in breast-fed infants with and without supplemental vitamin D: one-year follow-up. J Pediatr 1982; 100:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/43\">",
"      Neville MC, Watters CD. Secretion of calcium into milk: review. J Dairy Sci 1983; 66:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/44\">",
"      Jones G, Riley M, Dwyer T. Breastfeeding in early life and bone mass in prepubertal children: a longitudinal study. Osteoporos Int 2000; 11:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/45\">",
"      Casey CE, Hambidge KM, Neville MC. Studies in human lactation: zinc, copper, manganese and chromium in human milk in the first month of lactation. Am J Clin Nutr 1985; 41:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/46\">",
"      Dallman PR, Siimes MA, Stekel A. Iron deficiency in infancy and childhood. Am J Clin Nutr 1980; 33:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6727/abstract/47\">",
"      L&ouml;nnerdal B, Hernell O. Iron, zinc, copper and selenium status of breast-fed infants and infants fed trace element fortified milk-based infant formula. Acta Paediatr 1994; 83:367.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5012 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6727=[""].join("\n");
var outline_f6_36_6727=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50899589\">",
"      ENERGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NITROGEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Whey and casein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Non-protein nitrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Nucleotides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LIPID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CARBOHYDRATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MINERAL AND TRACE ELEMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      VITAMINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=related_link\">",
"      Breastfeeding: Parental education and support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10680?source=related_link\">",
"      Clinical features and etiology of colic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=related_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29640?source=related_link\">",
"      Milk allergy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=related_link\">",
"      Overview of the routine management of the healthy newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=related_link\">",
"      Patient information: Breast pumps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=related_link\">",
"      Patient information: Common breastfeeding problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=related_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=related_link\">",
"      Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6519?source=related_link\">",
"      Physiology of lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_36_6728="Thin-cap fibroatheroma with intraplaque hemorrhage";
var content_f6_36_6728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Thin-cap fibroatheroma with intraplaque hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thin-cap fibroatheroma with recent intraplaque hemorrhage.",
"    <br>",
"     (1A) Low (x20) and (1B) higher-power (x200) views of a thin-cap fibroatheroma with recent hemorrhage. Note, in 1B there is spillage of erythrocytes from surrounding intraplaque vasa vasorum (arrow).",
"     <br>",
"      (2A, 2B) Serial section of the lesion in Panel 1A shows a large pool of extravasated erythrocytes with proximate micro-vessels (arrow). Panel 2B is a high-power view of boxed area in Panel 2A.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005; 25:2054. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6728=[""].join("\n");
var outline_f6_36_6728=null;
var title_f6_36_6729="Bacillus cereus and other non-anthracis Bacillus species";
var content_f6_36_6729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bacillus cereus and other non-anthracis Bacillus species",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/36/6729/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/36/6729/contributors\">",
"     Lisa Noonan, MSc, MBChB, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/36/6729/contributors\">",
"     Joshua Freeman, MBChB, FRCPA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/36/6729/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/36/6729/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/36/6729/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/36/6729/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/36/6729/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H453848234\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Bacillus cereus group is comprised of six closely related species: B. cereus, B. mycoides, B. pseudomycoides, B. thuringiensis, B. weihenstephanensis, and B. anthracis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Most human Bacillus infections are caused by B. cereus, although infections with other species within the B. cereus group have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to B. cereus and other non-anthracis Bacillus species will be reviewed here. Issues related to B. anthracis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39079?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7224?source=see_link\">",
"     \"Clinical manifestations and diagnosis of anthrax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32232?source=see_link\">",
"     \"Treatment of anthrax\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19835826\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Members of the Bacillus cereus group are catalase positive, aerobic (or facultatively anaerobic), spore-forming gram-positive bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/5\">",
"     5",
"    </a>",
"    ]. Occasionally B. cereus may appear gram-variable or even gram-negative with age. In Gram stains of body fluids, B. cereus appears straight or slightly curved with square ends arranged either alone or in short chains. Junctions between members of the chain are clearly visible. Gram staining of B. cereus taken from agar colonies tends to have a more uniform bacillary appearance ranging in size from 3 by 0.4 microns up to 9 by 2 microns. B. cereus present in tissue sections may appear long and filamentous. Spores are not always visible on Gram stain but when apparent they are located centrally, do not distort the bacillary shape, and are clear in appearance. Spores can be stained using specific dyes (eg, malachite green) that are absorbed by spores in the presence of heat.",
"   </p>",
"   <p>",
"    Bacillus species are easily recovered on blood and chocolate agars and grow optimally at environmental temperatures (25 to 37C). All species except B. anthracis are motile and beta-hemolytic on blood agar. Colonies have an irregular perimeter and appear dull gray and opaque on sheep blood agar. On egg yolk agar, members of the B. cereus group produce a zone of opacification due to lecithinase production.",
"   </p>",
"   <p>",
"    Individual species within the B. cereus group cannot usually be differentiated by diagnostic laboratories (with the exception of B. anthracis, which is non-motile and non-hemolytic). Therefore, distinguishing individual species within the B. cereus group usually requires specialized molecular testing by a reference laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phenotypic differences between member-species of the B. cereus group are largely due to the presence of extra-chromosomal plasmids [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. For example, B. thuringiensis carries a plasmid that encodes toxins that are pathogenic for a variety of insects. The presence of this plasmid in B. thuringiensis forms the basis for its use as a commercial larvicide and insecticide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26412822\">",
"    <span class=\"h2\">",
"     Susceptibility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of methods have been used to evaluate the susceptibility of Bacillus spp isolates to a variety of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. In one study, 89 blood culture isolates of non-anthracis Bacillus spp (including 54 isolates of the B. cereus group) underwent antibiotic susceptibility testing against 18 different antibiotics by disk diffusion and broth microdilution [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/11\">",
"     11",
"    </a>",
"    ]. All isolates of B. cereus were susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , imipenem, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , but resistant to penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    , and cephalosporins. Variable susceptibilities were observed against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    . Isolates of Bacillus spp other than the B. cereus group were more sensitive to penicillins than those of the B. cereus group (75 to 90 percent were susceptible to penicillin, cephazolin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    , and oxacillin). All isolates were susceptible to chloramphenicol, imipenem, and vancomycin.",
"   </p>",
"   <p>",
"    In another study of susceptibility for isolates of B. cereus, B. mycoides, B. pseudomycoides, and B. thuringiensis, most B. cereus isolates were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , penicillin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/10\">",
"     10",
"    </a>",
"    ]. Resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    was observed in 14 and 17 percent of isolates, respectively. All isolates were susceptible to the following antibiotics:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     quinupristin/dalfopristin,",
"    </span>",
"    rifampicin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    . The majority of B. mycoides, B. pseudomycoides, and B. thuringiensis isolates exhibited resistance to penicillins and cephalosporins. Most of the isolates tested were resistant to cotrimoxazole at 30&deg;C [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848262\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenic potential of the B. cereus group is largely due to a variety of secreted enzymes and toxins. Two different types of enterotoxins are produced by B. cereus: the diarrheal enterotoxin and the emetic toxin. The transcriptional virulence regulator PlcR (Phospholipase C Regulator) controls the expression of most virulence factors (eg, enterotoxins, hemolysins, phospholipases, and proteases) by binding upstream of controlled genes to a sequence called the PlcR box [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848248\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Members of the Bacillus cereus group are saprophytic environmental bacteria that are ubiquitous in nature. In particular, members of the Bacillus cereus group are abundant in soil, fresh water, marine water, and the intestinal tract of soil-dwelling insects. The capability for spore formation means that B. cereus can survive in the environment for extended periods and withstand extremes of temperature. Spores and vegetative bacteria frequently contaminate food. Not surprisingly therefore, B. cereus is found as a transient but normal component of the human gastrointestinal flora. Stool recovery rates in healthy asymptomatic individuals range from 0 to 43 percent, and the strains recovered are similar to those recovered from the food supply [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Isolates of Bacillus cereus are usually considered contaminants when cultured from clinical",
"    <span class=\"nowrap\">",
"     specimens/sterile",
"    </span>",
"    sites. However, B. cereus can also be an important cause of infection, particularly in patients with prosthetic devices, neonates, and intravenous drug users. The association between intravenous drug use and bacteremia with Bacillus cereus is due to contamination of needles and injected material with Bacillus cereus. In several studies, Bacillus species were the organisms most frequently recovered from samples of street heroin and intravenous drug paraphernalia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. B. cereus has also been associated with alcohol prep pad contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848269\">",
"    <span class=\"h2\">",
"     Pseudo-epidemics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacillus species are common blood culture contaminants, accounting for 0.1 to 0.9 percent of all blood cultures submitted [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/20\">",
"     20",
"    </a>",
"    ]. Contamination of cerebrospinal fluid (CSF) has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/21\">",
"     21",
"    </a>",
"    ]. One multi-center study from Israel suggested that isolation of Bacillus species from blood culture is seasonal, peaking during late summer and early autumn; the underlying reasons for this observation are uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sharp increases in the rate of contamination of clinical specimens are known as pseudo-epidemics. Pseudo-epidemics of B. cereus in the hospital setting have been linked to contaminated ethanol solution [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/23\">",
"     23",
"    </a>",
"    ], contaminated hospital linen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/24\">",
"     24",
"    </a>",
"    ], contaminated blood culture media [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/25\">",
"     25",
"    </a>",
"    ], contaminated gloves [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/26\">",
"     26",
"    </a>",
"    ], and hospital construction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848402\">",
"    <span class=\"h2\">",
"     Hospital outbreaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genuine hospital outbreaks of Bacillus cereus infections have also been reported, usually linked to contaminated medical equipment, such as ventilators and dialysis circuits [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. It is important to differentiate genuine hospital outbreaks from pseudo-epidemics, although both may occur concurrently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848276\">",
"    <span class=\"h1\">",
"     CLINICAL SYNDROMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848283\">",
"    <span class=\"h2\">",
"     Food poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacillus cereus is able to persist in food processing environments due to its ability to survive at extreme temperatures as well as its ability to form biofilms and spores. B. cereus has been recovered from a wide range of foods, including rice, dairy products, spices, bean sprouts and other vegetables. Fried rice is an important cause of emetic-type food poisoning associated with B. cereus in the United States. The organism is frequently present in uncooked rice, and heat-resistant spores may survive cooking. Cooked rice subsequently at room temperature can allow vegetative forms to multiply, and the heat-stable toxin that is produced can survive brief heating such as stir frying [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two distinct types of toxin-mediated food poisoning are caused by B. cereus, characterized by either diarrhea or vomiting, depending on which toxin is involved. The diarrheal toxin is produced by vegetative cells in the small intestine after ingestion of either bacilli or spores. The emetic toxin is ingested directly from contaminated food [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/13\">",
"     13",
"    </a>",
"    ]. Both toxins cause disease within 24 hours of ingestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848290\">",
"    <span class=\"h3\">",
"     Diarrheal syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diarrheal syndrome is characterized by abdominal cramps and copious diarrhea, usually beginning 8 to 16 hours after ingestion and resolving within 24 hours. Vomiting is uncommon. The diarrheal syndrome is caused by at least three pore-forming",
"    <span class=\"nowrap\">",
"     cytotoxins/enterotoxins",
"    </span>",
"    that are secreted by ingested vegetative cells: hemolysin BL (Hbl), non-hemolytic enterotoxin (Nhe), and cytotoxin K [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/13\">",
"     13",
"    </a>",
"    ]. The diarrheal cytotoxins are heat labile; their viability is considerably reduced by adequately heating food [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/31\">",
"     31",
"    </a>",
"    ]. Foods that have been linked to diarrheal toxin-mediated disease caused by B cereus include meats, vegetables, and sauces. The infective dose of toxin-producing B. cereus for diarrheal disease is 10",
"    <sup>",
"     5",
"    </sup>",
"    to 10",
"    <sup>",
"     8",
"    </sup>",
"    cfu cells per gram of food [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848304\">",
"    <span class=\"h3\">",
"     Emetic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emetic syndrome is caused by direct ingestion of the toxin cereulide, which is a small ring-formed peptide encoded by plasmid DNA. The number of viable spores and vegetative bacteria that produce diarrheal toxin is reduced by heating, although spores associated with emetic toxin are capable of surviving heat processing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/31\">",
"     31",
"    </a>",
"    ]. Cereulide is heat stable and resistant to gastric conditions. The ingested toxin itself may therefore cause disease despite sufficient heating to kill B cereus.",
"   </p>",
"   <p>",
"    The emetic syndrome is characterized by abdominal cramps, nausea, and vomiting. Diarrhea also occurs in about one-third of individuals. Symptom onset is usually within one to five hours of ingestion, but it can also occur within half an hour and up to six hours after ingestion of contaminated food [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/32\">",
"     32",
"    </a>",
"    ]. Symptoms usually resolve in 6 to 24 hours. Rice based dishes in particular have been implicated in emetic toxin mediated disease, usually as a result of cooling fried rice dishes overnight at room temperature followed by reheating the next day. The infective dose of cereulide required to cause symptoms is 8 to 10 micrograms per kilogram of body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main differential diagnosis is Staphylococcus aureus enterotoxin related gastroenteritis, which is also emetic but usually accompanied by diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=see_link&amp;anchor=H8#H8\">",
"     \"Differential diagnosis of microbial foodborne disease\", section on 'Staphylococcus aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848509\">",
"    <span class=\"h2\">",
"     Bacteremia and endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiating true bacteremia from contamination due to Bacillus spp can be difficult. Most Bacillus species recovered from blood cultures are regarded as contaminants, although Bacillus species also cause true bloodstream infection.",
"   </p>",
"   <p>",
"    True bacteremia is likely present if Bacillus spp is isolated from both bottles of a single set of blood cultures, or isolated repeatedly from multiple blood cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. A retrospective review of Bacillus species blood isolates in one hospital over a five year period concluded that 5 to 10 percent of isolates represented clinically significant pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most bloodstream infections due to Bacillus species in adults are due to central line related infections. The rate of relapse is high in settings where antimicrobial therapy is administered but the central line is not removed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H453848346\">",
"     'Bacteremia and endocarditis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are several reports of Bacillus bacteremia in neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/36\">",
"     36",
"    </a>",
"    ]. Among these patients, a report of a gram-positive bacillus isolated from blood culture may initially be assumed to be Listeria monocytogenes, causing a delay in appropriate management. In a report of clinically significant infections due to B. cereus in 21 infants, 12 were blood stream infections; additional sites were also involved in some cases, including the central nervous system (11 cases) or the respiratory tract (5 cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/36\">",
"     36",
"    </a>",
"    ]. In general, neonates and infants with bacteremia due to Bacillus spp should also be evaluated for central nervous system involvement. (See",
"    <a class=\"local\" href=\"#H453848495\">",
"     'Central nervous system infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Endocarditis due to B. cereus is associated with intravenous drug use [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/18\">",
"     18",
"    </a>",
"    ], prosthetic heart valves [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/37\">",
"     37",
"    </a>",
"    ], and indwelling pacemakers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/38\">",
"     38",
"    </a>",
"    ]. B. cereus native valve endocarditis in the absence of underlying valvular abnormalities or other risk factors is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/37\">",
"     37",
"    </a>",
"    ]. Complications associated with B. cereus prosthetic valve endocarditis include thromboembolic events and valvular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848311\">",
"    <span class=\"h2\">",
"     Musculoskeletal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue and bone infection due to B. cereus has been associated with trauma, intravenous drug use, and immune compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/18\">",
"     18",
"    </a>",
"    ]. Musculoskeletal infections with B. cereus have been reported after a wide variety of trauma mechanisms including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gunshot wounds [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Tropical traumatic wounds acquired in Costa Rica [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Open fractures with environmental contamination [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Post-operative and traumatic orthopaedic wounds [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bear bites [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Plaster associated wound infection [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Burn wounds infected by contaminated water [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Scalp infection [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cellulitis from contaminated heroin [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Necrotizing soft tissue infection due to B. cereus may resemble Clostridial infection. It has been described in the setting of injection drug use, diabetes mellitus, immune compromise, trauma, and as a result of subcutaneous injection of contaminated heroin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/18,49-51\">",
"     18,49-51",
"    </a>",
"    ]. Superinfection with Bacillus spp has also been described in the setting of chronic osteomyelitis due to Staphylococcus aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848495\">",
"    <span class=\"h2\">",
"     Central nervous system infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system (CNS) infections due to Bacillus spp have been described in adults and neonates. Manifestations have included cases of infected subarachnoid hemorrhage, meningoencephalitis, and brain abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. CNS infections due to Bacillus spp in adults have been associated with hematological malignancy and neurosurgery. The risk of infection may be increased in the setting of external ventricular drains [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CNS infection has also been described among children and neonates. In one small series of four children with Bacillus cereus bacteremia and CNS infection in the setting of leukemia, risk factors for fulminant disease included neutropenia, relapsed disease, induction chemotherapy, use of corticosteroids or third generation cephalosporins, recent hospitalization, and recent lumbar puncture with intrathecal chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/56\">",
"     56",
"    </a>",
"    ]. The mechanism of CNS infection in these cases is most likely attributable to chemical arachnoiditis induced by intrathecal chemotherapy with secondary seeding in the setting of bacteremia (rather than introduction of Bacillus spp at the time of lumbar puncture) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neonates may also have CNS involvement in the setting of B. cereus bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In one review including 21 cases of neonatal bacteremia, 11 also had evidence of CNS infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24425853\">",
"    <span class=\"h2\">",
"     Ocular infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular manifestations include endophthalmitis and keratitis.",
"   </p>",
"   <p>",
"    Endophthalmitis due to Bacillus species is a serious condition that progresses rapidly and can threaten vision within hours of the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Ocular trauma accounts for 70 to 87 percent of cases of B. cereus endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/60,62,63\">",
"     60,62,63",
"    </a>",
"    ]; the remaining cases occur secondary to hematogenous seeding [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/16,60,63\">",
"     16,60,63",
"    </a>",
"    ] or as a complication of ocular surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/63\">",
"     63",
"    </a>",
"    ]. Endophthalmitis due to B. cereus is associated with poor outcomes. In a series of 15 cases of endophthalmitis due to Bacillus species (most patients due to penetrating ocular injuries) with relatively early initiation of treatment, poor visual outcomes occurred in approximately one-half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/63\">",
"     63",
"    </a>",
"    ]. Similarly, in a review of 82 cases of Bacillus spp endophthalmitis, 46 percent of patients were left with either perception of light only or no perception of light [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Keratitis caused by Bacillus spp usually occurs in the setting of traumatic corneal abrasions but can also occur as a complication of wearing contact lenses or cataract surgery. Keratitis usually has a more indolent clinical course than endophthalmitis; patients may present weeks or months after the initial corneal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/2,65\">",
"     2,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19836048\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outbreaks of B. cereus food poisoning usually obtain laboratory confirmation through specialized public health reference laboratories rather than laboratories providing routine diagnostic services. Besides culture of B. cereus from stool, several commercial assays can be used to detect the diarrheal toxin. These include a reverse passive latex agglutination test [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/66\">",
"     66",
"    </a>",
"    ], immunochromatographic tests, and polymerase chain reaction (PCR) that targets the gene itself [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. PCR assays have also been used successfully for diagnosis of emetic food borne B. cereus infection. As the emetic toxin is heat stable, it can cause disease despite heating the food sufficiently to kill B cereus. Thus culture of vomitus may be negative for B. cereus despite the presence of emetic toxin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848332\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848538\">",
"    <span class=\"h2\">",
"     Empiric antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are not indicated for treatment of food poisoning caused by B. cereus. Empiric antibiotic therapy is warranted for treatment of other clinical syndromes, including bacteremia, device related infections, endocarditis, musculoskeletal infection, central nervous system (CNS) infection, and ocular infection. Once in vitro susceptibility testing is available, antibiotic selection for treatment of Bacillus spp infections should be guided by these results. (See",
"    <a class=\"local\" href=\"#H26412822\">",
"     'Susceptibility testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most B. cereus isolates produce beta-lactamases and are resistant to penicillins and cephalosporins. For this reason, penicillins and cephalosporins should not be used for empiric treatment of Bacillus infection. Prior to the availability of susceptibility testing,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is generally considered the preferred antibiotic choice. Alternative agents that have in vitro activity against Bacillus spp include aminoglycosides, carbapenems, and fluoroquinolones.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    should not be used until the results of susceptibility testing become available; there is in vitro evidence of both outright and inducible clindamycin resistance among clinical isolates of B. cereus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are limited regarding use of combination therapy. Bactericidal synergy between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    as well as gentamicin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    has been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/12\">",
"     12",
"    </a>",
"    ]. Some reports of serious infections due to non-anthracis Bacillus species have described treatment with vancomycin or clindamycin, plus or minus an aminoglycoside [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/16,39,59,69\">",
"     16,39,59,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26412970\">",
"    <span class=\"h2\">",
"     Food poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of food poisoning due to B. cereus consists of symptomatic measures; antibiotics are not indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848346\">",
"    <span class=\"h2\">",
"     Bacteremia and endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of bacteremia due to Bacillus spp consists of intravascular catheter removal (if present) and antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/70\">",
"     70",
"    </a>",
"    ]. Appropriate therapy consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (or alternative agent to which the isolate is known to be susceptible) for 7 to 14 days following catheter removal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/4\">",
"     4",
"    </a>",
"    ]. Data on duration of therapy are limited; seven days is generally sufficient in the setting of clinical resolution of symptoms. Evidence of persistent bacteremia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fever warrants longer duration of therapy together with investigation for metastatic site(s) of infection.",
"   </p>",
"   <p>",
"    Poor outcomes due to B. cereus bacteremia have been described among neonates and infants; in one study including 22 patients, the mortality rate was 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/36\">",
"     36",
"    </a>",
"    ]. In general, neonates and infants with bacteremia due to Bacillus spp should also be evaluated for CNS involvement.",
"   </p>",
"   <p>",
"    Data on management of endocarditis due to Bacillus spp is limited to case report literature [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/37,39,71\">",
"     37,39,71",
"    </a>",
"    ]. In general treatment consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (or alternative agent to which the isolate is known to be susceptible) for at least six weeks. Management of prosthetic valve endocarditis usually requires valve replacement in addition to antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26413016\">",
"    <span class=\"h2\">",
"     Musculoskeletal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of musculoskeletal infection due to Bacillus spp consists of debridement and antimicrobial therapy. Appropriate antimicrobial therapy consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (or alternative agent to which the isolate is known to be susceptible) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/1,52\">",
"     1,52",
"    </a>",
"    ]. Treatment of osteomyelitis generally requires a prolonged course of therapy (6 to 12 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/18,52\">",
"     18,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848367\">",
"    <span class=\"h2\">",
"     Central nervous system infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of CNS infection due to Bacillus spp usually consists of combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and an aminoglycoside. Depending upon susceptibility results, a carbapenem may be a suitable alternative. The duration of treatment should be tailored to individual patient circumstances; in general meningoencephalitis should be treated for at least 14 days and brain abscesses should generally be treated for at least six weeks.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    should not be used to treat CNS infections because it is bacteriostatic and does not attain therapeutic concentrations in the cerebrospinal fluid.",
"   </p>",
"   <p>",
"    The presence of external ventricular drains increases the risk of infection with Bacillus spp [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/35\">",
"     35",
"    </a>",
"    ]. In the setting of infection, these devices should be removed if present [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848381\">",
"    <span class=\"h2\">",
"     Ocular infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of endophthalmitis due to Bacillus spp consists of surgical management together with antimicrobial therapy (intraocular and systemic administration) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/4,60,63,73\">",
"     4,60,63,73",
"    </a>",
"    ]. Early initiation of treatment is critical. Appropriate antimicrobial therapy consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (with or without an aminoglycoside) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is an acceptable alternative agent if the isolate is known to be susceptible; parenteral or subconjunctival administration of clindamycin can achieve therapeutic levels in the iris, choroid, and vitreous. Some data suggest that combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    and vancomycin or clindamycin may be synergistic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6729/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453848388\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most human Bacillus infections are caused by B. cereus, although infections with other species within the B. cereus group have also been described. Members of the Bacillus cereus group are catalase positive, aerobic (or facultatively anaerobic), spore-forming gram-positive bacilli. Bacillus species are easily recovered on blood and chocolate agars and grow optimally at environmental temperatures. (See",
"      <a class=\"local\" href=\"#H453848234\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19835826\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Members of the Bacillus cereus group are abundant in the environment. Spore formation enables B. cereus to survive in the environment for extended periods and withstand extremes of temperature. Spores and vegetative bacteria can contaminate food, causing gastrointestinal illness. The organism can also contaminate drug injection paraphernalia as well as prosthetic devices and other healthcare equipment. (See",
"      <a class=\"local\" href=\"#H453848248\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacillus species are common blood culture contaminants. Genuine hospital outbreaks of Bacillus cereus infections have also been reported, usually linked to contaminated medical equipment, such as ventilators and dialysis circuits. (See",
"      <a class=\"local\" href=\"#H453848269\">",
"       'Pseudo-epidemics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H453848402\">",
"       'Hospital outbreaks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two distinct types of toxin-mediated food poisoning are caused by B. cereus, characterized by either diarrhea or vomiting, depending on which toxin is involved. The diarrheal toxin is produced by vegetative cells in the small intestine after ingestion of either bacilli or spores. The emetic toxin is ingested directly from contaminated food. Both toxins cause disease within 24 hours of ingestion. (See",
"      <a class=\"local\" href=\"#H453848283\">",
"       'Food poisoning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other clinical syndromes caused by B. cereus include bacteremia, endocarditis, musculoskeletal infection, central nervous system (CNS) infection, and ocular infection. There are several reports of neonatal bacteremia and CNS infection due to Bacillus. (See",
"      <a class=\"local\" href=\"#H453848276\">",
"       'Clinical syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotic therapy is not indicated for treatment of food poisoning caused by B. cereus. Antibiotic therapy is warranted for treatment of bacteremia, device related infections, endocarditis, musculoskeletal infection, CNS infection, and ocular infection. (See",
"      <a class=\"local\" href=\"#H453848538\">",
"       'Empiric antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most B. cereus isolates produce beta-lactamases and are resistant to penicillins and cephalosporins. Prior to the availability of susceptibility testing, we suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      be included in empiric treatment regimens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternative agents that have in vitro activity against Bacillus spp include aminoglycosides, carbapenems, and fluoroquinolones.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      resistance has been described, so this agent should not be used in the absence of susceptibility data. (See",
"      <a class=\"local\" href=\"#H453848538\">",
"       'Empiric antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Fekete T. Bacillus species and related genera other than Bacillus anthracis. In: Principles and Practice of Infectious Diseases, Mandell GL,  Bennett JE, Dolin RM (Eds), Churchill Livingston, New York City 2010. p.2727.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/2\">",
"      Drobniewski FA. Bacillus cereus and related species. Clin Microbiol Rev 1993; 6:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/3\">",
"      Bottone EJ. Bacillus cereus, a volatile human pathogen. Clin Microbiol Rev 2010; 23:382.",
"     </a>",
"    </li>",
"    <li>",
"     Tuazon CU. Bacillus species. In: Antimicrobial therapy and vaccines I, Yu VL, Weber R, Raoult D (Eds), Apple Trees Production, New York City 2002. p.73.",
"    </li>",
"    <li>",
"     Logan NA, Popovic T, Hoffmaster A. Bacillus and other aerobic endospore forming bacterai. In: Manual of Clinical Microbiology, Murray PR, Baron EJ, Jorgensen JH, et al (Eds), American Society for Microbiology Press, Washington, DC 2007. p.455.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/6\">",
"      Guinebreti&egrave;re MH, Thompson FL, Sorokin A, et al. Ecological diversification in the Bacillus cereus Group. Environ Microbiol 2008; 10:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/7\">",
"      Rasko DA, Altherr MR, Han CS, Ravel J. Genomics of the Bacillus cereus group of organisms. FEMS Microbiol Rev 2005; 29:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/8\">",
"      Helgason E, Okstad OA, Caugant DA, et al. Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis--one species on the basis of genetic evidence. Appl Environ Microbiol 2000; 66:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/9\">",
"      Turnbull PC, Sirianni NM, LeBron CI, et al. MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol 2004; 42:3626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/10\">",
"      Luna VA, King DS, Gulledge J, et al. Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods. J Antimicrob Chemother 2007; 60:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/11\">",
"      Weber DJ, Saviteer SM, Rutala WA, Thomann CA. In vitro susceptibility of Bacillus spp. to selected antimicrobial agents. Antimicrob Agents Chemother 1988; 32:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/12\">",
"      Tanaka M, Isogai E, Isogai H, et al. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother 2002; 49:1039.",
"     </a>",
"    </li>",
"    <li>",
"     Stenfors Arnesen, LP, Fagerlund, A, and Granum, PE. From soil to gut: Bacillus cereus and its food poisoning toxins. FEMS Microbiol Rev 2008; 32:5579.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/14\">",
"      Gohar M, Faegri K, Perchat S, et al. The PlcR virulence regulon of Bacillus cereus. PLoS One 2008; 3:e2793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/15\">",
"      Turnbull PC, Kramer JM. Intestinal carriage of Bacillus cereus: faecal isolation studies in three population groups. J Hyg (Lond) 1985; 95:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/16\">",
"      Shamsuddin D, Tuazon CU, Levy C, Curtin J. Bacillus cereus panophthalmitis: source of the organism. Rev Infect Dis 1982; 4:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/17\">",
"      Tuazon CU, Hill R, Sheagren JN. Microbiologic study of street heroin and injection paraphernalia. J Infect Dis 1974; 129:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/18\">",
"      Tuazon CU, Murray HW, Levy C, et al. Serious infections from Bacillus sp. JAMA 1979; 241:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: Contamination of alcohol prep pads with Bacillus cereus group and Bacillus species--Colorado, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/20\">",
"      Pearson HE. Human infections caused by organisms of the bacillus species. Am J Clin Pathol 1970; 53:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/21\">",
"      Cunha BA, Schoch PE, Bonoan JT. Bacillus species pseudomeningitis. Heart Lung 1997; 26:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/22\">",
"      Ashkenazi-Hoffnung L, Kaufman Z, Bromberg M, et al. Seasonality of Bacillus species isolated from blood cultures and its potential implications. Am J Infect Control 2009; 37:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/23\">",
"      Hsueh PR, Teng LJ, Yang PC, et al. Nosocomial pseudoepidemic caused by Bacillus cereus traced to contaminated ethyl alcohol from a liquor factory. J Clin Microbiol 1999; 37:2280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/24\">",
"      Barrie D, Hoffman PN, Wilson JA, Kramer JM. Contamination of hospital linen by Bacillus cereus. Epidemiol Infect 1994; 113:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/25\">",
"      Noble RC, Reeves SA. Bacillus species pseudosepsis caused by contaminated commercial blood culture media. JAMA 1974; 230:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/26\">",
"      York MK. Bacillus species pseudobacteremia traced to contaminated gloves used in collection of blood from patients with acquired immunodeficiency syndrome. J Clin Microbiol 1990; 28:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/27\">",
"      Loeb M, Wilcox L, Thornley D, et al. Bacillus species pseudobacteremia following hospital construction. Can J Infect Control 1995; 10:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/28\">",
"      Bryce EA, Smith JA, Tweeddale M, et al. Dissemination of Bacillus cereus in an intensive care unit. Infect Control Hosp Epidemiol 1993; 14:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/29\">",
"      Curtis JR, Wing AJ, Coleman JC. Bacillus cereus bacteraemia. A complication of intermittent haemodialysis. Lancet 1967; 1:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/30\">",
"      Centers for Disease Control and Prevention (CDC). Bacillus cereus food poisoning associated with fried rice at two child day care centers--Virginia, 1993. MMWR Morb Mortal Wkly Rep 1994; 43:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/31\">",
"      Ankolekar C, Labb&eacute; RG. Survival during cooking and growth from spores of diarrheal and emetic types of Bacillus cereus in rice. J Food Prot 2009; 72:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/32\">",
"      Ehling-Schulz M, Fricker M, Scherer S. Bacillus cereus, the causative agent of an emetic type of food-borne illness. Mol Nutr Food Res 2004; 48:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/33\">",
"      Weber DJ, Saviteer SM, Rutala WA, Thomann CA. Clinical significance of Bacillus species isolated from blood cultures. South Med J 1989; 82:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/34\">",
"      Cotton DJ, Gill VJ, Marshall DJ, et al. Clinical features and therapeutic interventions in 17 cases of Bacillus bacteremia in an immunosuppressed patient population. J Clin Microbiol 1987; 25:672.",
"     </a>",
"    </li>",
"    <li>",
"     Kuroki, R, Kawakami, K, Qin, L, et al. Nosocomial bacteremia casued by biofilm-forming Bacillus cereus and Bacillus thuringiensis. Inter Med 2009; 48:791.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/36\">",
"      Hilliard NJ, Schelonka RL, Waites KB. Bacillus cereus bacteremia in a preterm neonate. J Clin Microbiol 2003; 41:3441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/37\">",
"      Steen MK, Bruno-Murtha LA, Chaux G, et al. Bacillus cereus endocarditis: report of a case and review. Clin Infect Dis 1992; 14:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/38\">",
"      Abusin S, Bhimaraj A, Khadra S. Bacillus Cereus Endocarditis in a permanent pacemaker: a case report. Cases J 2008; 1:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/39\">",
"      Castedo E, Castro A, Martin P, et al. Bacillus cereus prosthetic valve endocarditis. Ann Thorac Surg 1999; 68:2351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/40\">",
"      Krause A, Freeman R, Sisson PR, Murphy OM. Infection with Bacillus cereus after close-range gunshot injuries. J Trauma 1996; 41:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/41\">",
"      Dryden MS, Kramer JM. Toxigenic Bacillus cereus as a cause of wound infections in the tropics. J Infect 1987; 15:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/42\">",
"      Dubouix A, Bonnet E, Alvarez M, et al. Bacillus cereus infections in Traumatology-Orthopaedics Department: retrospective investigation and improvement of healthcare practices. J Infect 2005; 50:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/43\">",
"      Akesson A, Hedstr&ouml;m SA, Ripa T. Bacillus cereus: a significant pathogen in postoperative and post-traumatic wounds on orthopaedic wards. Scand J Infect Dis 1991; 23:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/44\">",
"      Kunimoto D, Rennie R, Citron DM, Goldstein EJ. Bacteriology of a bear bite wound to a human: case report. J Clin Microbiol 2004; 42:3374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/45\">",
"      Rutala WA, Saviteer SM, Thomann CA, Wilson MB. Plaster-associated Bacillus cereus wound infection. A case report. Orthopedics 1986; 9:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/46\">",
"      Ribeiro NF, Heath CH, Kierath J, et al. Burn wounds infected by contaminated water: case reports, review of the literature and recommendations for treatment. Burns 2010; 36:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/47\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of cutaneous Bacillus cereus infections among cadets in a university military program--Georgia, August 2004. MMWR Morb Mortal Wkly Rep 2005; 54:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/48\">",
"      Dancer SJ, McNair D, Finn P, Kolsto AB. Bacillus cereus cellulitis from contaminated heroin. J Med Microbiol 2002; 51:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/49\">",
"      Sada A, Misago N, Okawa T, et al. Necrotizing fasciitis and myonecrosis \"synergistic necrotizing cellulitis\" caused by Bacillus cereus. J Dermatol 2009; 36:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/50\">",
"      Meredith FT, Fowler VG, Gautier M, et al. Bacillus cereus necrotizing cellulitis mimicking clostridial myonecrosis: case report and review of the literature. Scand J Infect Dis 1997; 29:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/51\">",
"      Darbar A, Harris IA, Gosbell IB. Necrotizing infection due to Bacillus cereus mimicking gas gangrene following penetrating trauma. J Orthop Trauma 2005; 19:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/52\">",
"      Schricker ME, Thompson GH, Schreiber JR. Osteomyelitis due to Bacillus cereus in an adolescent: case report and review. Clin Infect Dis 1994; 18:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/53\">",
"      Marley EF, Saini NK, Venkatraman C, Orenstein JM. Fatal Bacillus cereus meningoencephalitis in an adult with acute myelogenous leukemia. South Med J 1995; 88:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/54\">",
"      Mori T, Tokuhira M, Takae Y, et al. Successful non-surgical treatment of brain abscess and necrotizing fasciitis caused by Bacillus cereus. Intern Med 2002; 41:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/55\">",
"      Berke E, Collins WF, von Graevenitz A, Bia FJ. Fulminant postsurgical Bacillus cereus meningitis: case report. J Neurosurg 1981; 55:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/56\">",
"      Gaur AH, Patrick CC, McCullers JA, et al. Bacillus cereus bacteremia and meningitis in immunocompromised children. Clin Infect Dis 2001; 32:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/57\">",
"      Van Der Zwet WC, Parlevliet GA, Savelkoul PH, et al. Outbreak of Bacillus cereus infections in a neonatal intensive care unit traced to balloons used in manual ventilation. J Clin Microbiol 2000; 38:4131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/58\">",
"      Weisse ME, Bass JW, Jarrett RV, Vincent JM. Nonanthrax Bacillus infections of the central nervous system. Pediatr Infect Dis J 1991; 10:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/59\">",
"      Davey RT Jr, Tauber WB. Posttraumatic endophthalmitis: the emerging role of Bacillus cereus infection. Rev Infect Dis 1987; 9:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/60\">",
"      Hemady R, Zaltas M, Paton B, et al. Bacillus-induced endophthalmitis: new series of 10 cases and review of the literature. Br J Ophthalmol 1990; 74:26.",
"     </a>",
"    </li>",
"    <li>",
"     Miller, JJ, Scott, IU, Flynn Jr, HW, et al. Endopthalmitis caused by Bacillus species. Am J Ophthal 2008; 145:883.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/62\">",
"      Das T, Choudhury K, Sharma S, et al. Clinical profile and outcome in Bacillus endophthalmitis. Ophthalmology 2001; 108:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/63\">",
"      Miller JJ, Scott IU, Flynn HW Jr, et al. Endophthalmitis caused by Bacillus species. Am J Ophthalmol 2008; 145:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/64\">",
"      David DB, Kirkby GR, Noble BA. Bacillus cereus endophthalmitis. Br J Ophthalmol 1994; 78:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/65\">",
"      Pinna A, Sechi LA, Zanetti S, et al. Bacillus cereus keratitis associated with contact lens wear. Ophthalmology 2001; 108:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/66\">",
"      Granum PE, Brynestad S, Kramer JM. Analysis of enterotoxin production by Bacillus cereus from dairy products, food poisoning incidents and non-gastrointestinal infections. Int J Food Microbiol 1993; 17:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/67\">",
"      Das S, Surendran PK, Thampuran NK. PCR-based detection of enterotoxigenic isolates of Bacillus cereus from tropical seafood. Indian J Med Res 2009; 129:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/68\">",
"      Fricker M, Messelh&auml;usser U, Busch U, et al. Diagnostic real-time PCR assays for the detection of emetic Bacillus cereus strains in foods and recent food-borne outbreaks. Appl Environ Microbiol 2007; 73:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/69\">",
"      Chu WP, Que TL, Lee WK, Wong SN. Meningoencephalitis caused by Bacillus cereus in a neonate. Hong Kong Med J 2001; 7:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/70\">",
"      Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/71\">",
"      Block CS, Levy ML, Fritz VU. Bacillus cereus endocarditis. A case report. S Afr Med J 1978; 53:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/72\">",
"      Berner R, Heinen F, Pelz K, et al. Ventricular shunt infection and meningitis due to Bacillus cereus. Neuropediatrics 1997; 28:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6729/abstract/73\">",
"      Gigantelli JW, Torres Gomez J, Osato MS. In vitro susceptibilities of ocular Bacillus cereus isolates to clindamycin, gentamicin, and vancomycin alone or in combination. Antimicrob Agents Chemother 1991; 35:201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13998 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6729=[""].join("\n");
var outline_f6_36_6729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H453848388\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H453848234\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19835826\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26412822\">",
"      Susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H453848262\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H453848248\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453848269\">",
"      Pseudo-epidemics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453848402\">",
"      Hospital outbreaks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H453848276\">",
"      CLINICAL SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453848283\">",
"      Food poisoning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H453848290\">",
"      - Diarrheal syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H453848304\">",
"      - Emetic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453848509\">",
"      Bacteremia and endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453848311\">",
"      Musculoskeletal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453848495\">",
"      Central nervous system infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24425853\">",
"      Ocular infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19836048\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H453848332\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453848538\">",
"      Empiric antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26412970\">",
"      Food poisoning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453848346\">",
"      Bacteremia and endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26413016\">",
"      Musculoskeletal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453848367\">",
"      Central nervous system infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453848381\">",
"      Ocular infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H453848388\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7224?source=related_link\">",
"      Clinical manifestations and diagnosis of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=related_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39079?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32232?source=related_link\">",
"      Treatment of anthrax",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_36_6730="Drug-induced thrombosis and vascular disease in patients with malignancy";
var content_f6_36_6730=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug-induced thrombosis and vascular disease in patients with malignancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/36/6730/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/36/6730/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/36/6730/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/36/6730/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/36/6730/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/36/6730/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/36/6730/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer is often associated with a state of hypercoagulability, which can have a variety of clinical manifestations, including migratory superficial thrombophlebitis, \"unprovoked\" deep vein and other venous thrombosis, nonbacterial thrombotic endocarditis, and disseminated intravascular coagulation. Deep vein thrombosis is the most common vascular complication of antineoplastic therapy. Intracranial dural sinus vein thrombosis and thrombotic microangiopathies can also be seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review will discuss vascular complications caused by the various chemotherapeutic agents used in the treatment of patients with malignant disease. The pathogenesis of the hypercoagulable state associated with cancer and the cancer-related risk of hypercoagulable disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=see_link\">",
"     \"Pathogenesis of the hypercoagulable state associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Venous thromboembolism (VTE) prophylaxis in patients with cancer and treatment of malignancy-associated VTE are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H10#H10\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Prevention of VTE'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19367?source=see_link\">",
"     \"Treatment of venous thromboembolism in patients with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiovascular toxicities from antiangiogenic agents are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proposed mechanisms for the increased incidence of vascular complications in patients with malignancy include release or expression of procoagulants by tumor cells (eg, tissue factor) and expression of procoagulant activity by normal host cells such as monocytes, platelets, and endothelial cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=see_link\">",
"     \"Pathogenesis of the hypercoagulable state associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the usual treatments for cancer also significantly increase the risk of thrombotic events.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery is a major precipitating factor, with the risk of postoperative thrombosis being several-fold higher than in patients without cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H3#H3\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Risk factors for VTE'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High dose chemotherapy and bone marrow transplantation for hematologic malignancies are associated with an enhanced risk of thrombosis, particularly hepatic veno-occlusive disease, due to endothelial",
"      <span class=\"nowrap\">",
"       damage/dysfunction.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link\">",
"       \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A number of chemotherapeutic regimens have been associated with an increased rate of thromboembolism [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/1\">",
"       1",
"      </a>",
"      ]. Two of the agents associated with an increased risk of thrombosis are L-asparaginase, often given for acute lymphoblastic leukemia, and the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      in the prevention treatment of breast cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'L-asparaginase'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H10\">",
"       'Tamoxifen and raloxifene'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The presence of an indwelling central venous catheter is a known risk factor for the development of upper extremity venous thrombosis in both adult and pediatric cancer patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link\">",
"       \"Catheter-induced upper extremity venous thrombosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=see_link\">",
"       \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disease- and patient-specific risk factors may also contribute to the risk of chemotherapy-associated venous thromboembolic disease. In a study of 3003 patients receiving at least one cycle of chemotherapy, symptomatic VTE occurred in 1.9 percent over a median follow-up of 2.4 months, or a rate of 0.8",
"    <span class=\"nowrap\">",
"     percent/month",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/2\">",
"     2",
"    </a>",
"    ]. The highest rates were seen in patients with upper gastrointestinal cancers, lung cancer, and lymphoma, with rates of 2.3, 1.2, and 1.1",
"    <span class=\"nowrap\">",
"     percent/month,",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    On multivariate analysis, the following factors were significantly associated with development of symptomatic VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Upper gastrointestinal malignancy (odds ratio [OR] 3.9, 95% CI 1.4-10)",
"     </li>",
"     <li>",
"      Pre-chemotherapy platelet count",
"      <span class=\"nowrap\">",
"       &ge;350,000/microL",
"      </span>",
"      (OR 2.8, 95% CI 1.6-4.9)",
"     </li>",
"     <li>",
"      Use of white blood cell growth factors (eg, G-CSF, OR 2.1, 95% CI 1.2-3.6)",
"     </li>",
"     <li>",
"      Hemoglobin &lt;10.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or use of erythropoietin (OR 1.8, 95% CI 1.1-3.1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of chemotherapy initiation on the incidence of VTE was further examined in a retrospective study of 17,284 ambulatory patients with advanced cancer who were initiating systemic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/3\">",
"     3",
"    </a>",
"    ]. Data were extracted from a large health care claims database of commercially insured patients in the United States with five common solid tumors (lung, colorectal, bladder, ovarian, pancreatic, or gastric). Compared with age-matched controls, patients with advanced cancer had a nine-fold increased risk of VTE within the first year of initiating chemotherapy (12.6 percent versus 1.4 percent). The risk was highest within the first month of initiating chemotherapy. Eighteen percent of those who developed a VTE did so within the first month, 47 percent within the first three months, and 73 percent within the first six months. The rates of VTE in this study were significantly higher in this cohort than that reported in clinical trials of anticoagulation for VTE prevention (approximately 4 percent in patients with non-pancreatic solid tumors). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H15#H15\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Efficacy of anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     L-ASPARAGINASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic events have been reported with induction chemotherapy regimens for acute lymphoblastic leukemia (ALL) that include L-asparaginase. Intracranial dural sinus thrombosis with hemorrhage is observed most frequently, but deep venous thrombosis and pulmonary embolism can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. In one large series of children receiving L-asparaginase as part of induction chemotherapy for ALL, the incidence of thrombotic complications was 1.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/5\">",
"     5",
"    </a>",
"    ]. Generalized bleeding episodes have rarely been observed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asparaginase depletes plasma asparagine, thereby inhibiting protein synthesis in leukemic cells and the synthesis of many plasma proteins. The latter effect causes deficiencies of albumin, thyroxine-binding globulin, and various coagulation proteins, including prothrombin, factors V, VII, VIII, IX, X, XI, fibrinogen, antithrombin, protein C, protein S, and plasminogen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. This results in prolongation of the prothrombin time, activated partial thromboplastin time (aPTT), and thrombin time, and in hypofibrinogenemia with levels often less than 100",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    These coagulation abnormalities resolve within one to two weeks after cessation of the drug.",
"   </p>",
"   <p>",
"    It is difficult to assess the role of the substantial reductions in the levels of natural anticoagulant proteins such as antithrombin, protein C, and protein S in the pathogenesis of the thrombotic events. Both procoagulant and anticoagulant protein synthesis in the liver are decreased by L-asparaginase, leading to uncertainty as to whether there is an alteration in the balance of the opposing forces of the hemostatic mechanism. Two mechanisms have been considered and are discussed below",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antithrombin",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are data suggesting that antithrombin supplementation given concurrently with L-asparaginase may suppress the prothrombotic state [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. However, a drug-induced decrease in antithrombin is not predictive of subsequent thrombosis. In one study of children with ALL receiving L-asparaginase,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , no correlation was found between protein C, protein S, or antithrombin levels and the presence or absence of thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     von Willebrand factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Qualitatively abnormal von Willebrand factor (vWF) has been found in several patients at the time of L-asparaginase-induced thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/16\">",
"     16",
"    </a>",
"    ]. L-asparaginase may lead to a transient increase in unusually large plasma vWF multimers that have enhanced platelet-agglutinating properties [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Erwinia-asparaginase is an alternate preparation which may have fewer effects on the coagulation system than Escherichia coli L-asparaginase. In a series of 11 adults with ALL, there was significant lowering of antithrombin but the levels of the vitamin-K dependent procoagulant factors II, VII, and X, remained within normal ranges [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT OF BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies found an increased incidence of thromboembolic events in women with breast cancer treated with chemotherapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , or both. Additional risk factors may include postmenopausal status, prior mastectomy, increased body weight, presence of an indwelling central venous catheter, and evidence of coagulation activation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/18\">",
"     18",
"    </a>",
"    ]. With contemporary therapeutic regimens, the risk of thromboembolism appears to be less in breast cancer compared with other malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies of adjuvant chemotherapy for stage II breast cancer or primary chemotherapy for advanced, metastatic disease showed a high incidence of thrombosis, both arterial and venous, during but not after chemotherapy. The risk was higher in patients with metastatic disease, probably due to the increased tumor burden and the increased incidence of other predisposing factors such as immobilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of thromboembolic disease following chemotherapy for breast cancer varied widely in different reports, and appeared to be related to the stage of the disease, the chemotherapeutic regimen given (eg, CAF versus CMF), and whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    is given concurrently or following completion of chemotherapy (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Tamoxifen and raloxifene'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized study of early breast cancer, patients assigned to perioperative chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      had a higher incidence of thromboembolic events within six weeks after surgery than a control group treated with observation alone (2.1 versus 0.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Cancer and Leukemia Group B (CALGB) study, 433 patients were randomly assigned to receive one of three regimens based upon",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and 5-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      (CMF) as adjuvant therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/20\">",
"       20",
"      </a>",
"      ]. Thromboembolic disease occurred in 5 to 7 percent. There was no difference between the three groups. No patient developed thrombosis after chemotherapy was completed.",
"      <br/>",
"      <br/>",
"      A similar incidence (7 percent) was noted in a prospective study evaluated of 205 women with stage II breast cancer who were treated with one of two chemotherapy regimens: CMFVP (cyclophosphamide, methotrexate, fluorouracil,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) or CMFVP plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/21\">",
"       21",
"      </a>",
"      ]. Once again, no thrombotic episodes occurred during 2413 patient months of follow-up without therapy. There was no relationship between the development of thrombosis and estrogen or progesterone receptor status, age, number of involved lymph nodes, or subsequent tumor recurrence.",
"     </li>",
"     <li>",
"      A higher risk of thrombosis (18 percent) was noted in a series of 159 patients treated with CMFVP for advanced, stage IV disease [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/22\">",
"       22",
"      </a>",
"      ]. There were no differences in the presence of risk factors for thrombosis between the patients who had a thromboembolic event and those who did not.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although most patients develop venous thrombosis, there is also an association between arterial thrombosis and cancer therapy among women with breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. A CALGB study, for example, found a 1.3 percent incidence of arterial thrombosis, either peripheral or cerebrovascular, in 1014 patients during treatment for stage II or III breast cancer on two separate chemotherapy protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/23\">",
"     23",
"    </a>",
"    ]. All but one of the thrombotic events occurred while patients were receiving chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of the thrombogenic effects of chemotherapy in patients with breast cancer is not well understood. One report noted statistically significant decreases in protein C and protein S levels during CMF chemotherapy which, in some patients, fell below the range of values seen in hereditary thrombotic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/25\">",
"     25",
"    </a>",
"    ]. Reductions in procoagulants factor VII and fibrinogen were also present and none of the patients in this small series had clinically evident thrombosis. In another report, there were significant declines in protein C concentration during CMF chemotherapy, which returned to baseline values after the completion of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible explanations for these chemotherapy-induced abnormalities include impairment of vitamin K metabolism and inhibition of",
"    <span class=\"nowrap\">",
"     DNA/RNA",
"    </span>",
"    synthesis, leading to a reduction in protein synthesis by the liver. In addition, endothelial cell injury can lead to qualitative or quantitative abnormalities in vWF which may enhance the thrombotic potential. Other possible mechanisms include direct platelet activation, reduced fibrinolytic activity, and the release of procoagulant from tumor cells dying as a result of antineoplastic therapy.",
"   </p>",
"   <p>",
"    In one study, breast cancer patients had elevated levels of cell-free DNA (CFDNA) 24-hours postchemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/27\">",
"     27",
"    </a>",
"    ], a time point at which elevated thrombin-antithrombin levels had previously been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/28\">",
"     28",
"    </a>",
"    ]. CFDNA released from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    -treated whole blood significantly increased thrombin generation in a dose-dependent manner, and involved activation of the contact pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attempts to identify patients at risk by monitoring with coagulation tests have not been successful. In a study of 50 patients treated with adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    chemotherapy, the incidence of deep vein thrombosis was 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/29\">",
"     29",
"    </a>",
"    ]. Preoperative levels of D-dimer, fibrinogen, and plasminogen activator inhibitor activity were significantly higher in the patients with breast cancer than in healthy women; however, monitoring during chemotherapy did not identify patients at higher risk for deep vein thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tamoxifen and raloxifene",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies, including the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview analysis and the large Breast Cancer Prevention Trials, have demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    use is associated with an increased rate of",
"    <strong>",
"     venous",
"    </strong>",
"    thromboembolic events (2.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/30\">",
"     30",
"    </a>",
"    ]), especially within the first few years of tamoxifen use [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], and that there is a significant additional procoagulant effect when tamoxifen is added to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/24,33-40\">",
"     24,33-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H35#H35\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Tamoxifen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the NSABP P-1 Breast Cancer Prevention Trial (BCPT), which involved 13,388 women followed for an average of 3.6 years, the rates of pulmonary embolism and deep vein thrombosis were increased in older women receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      (risk ratio 3.0 [CI 1.1-11.2], and 1.6 [CI 0.9-2.9], respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/38\">",
"       38",
"      </a>",
"      ]. In a subsequent pooled analysis of 13 NSABP Breast Cancer Prevention trials, which involved 20,878 women, the risk of pulmonary embolism, deep venous thrombosis, and superficial phlebitis was increased two- to threefold in those treated with tamoxifen and was increased 11- to 15-fold in those treated with tamoxifen plus chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/39\">",
"       39",
"      </a>",
"      ]. In this trial and in a study from the Marshfield Clinic Personalized Medicine Research Project [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/41\">",
"       41",
"      </a>",
"      ], risk factors for VTE included increased age and body mass index. There were no differences in the rates of thrombosis between African Americans and white women in this study.",
"     </li>",
"     <li>",
"      In the five-year, randomized, double-blind, placebo-controlled International Breast Cancer Intervention Study (IBIS-1), involving 7139 patients, use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      was associated with an increased risk of developing a major venous thromboembolic event (odds ratio 2.1, 95% CI: 1.1-4.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/42\">",
"       42",
"      </a>",
"      ]. This risk was further increased in those patients who had surgery, immobilization, or fracture in the month prior to the event (odds ratio 4.7, 95% CI: 2.2-10.1).",
"     </li>",
"     <li>",
"      In a follow-up report from the IBIS-I trial, the risk of developing deep vein thrombosis or pulmonary embolus was significantly higher in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      arm than in the placebo arm during the five years of active treatment (RR 2.3, 95% CI 1.4-3.9), but not after tamoxifen was stopped (RR 1.1, 95% CI 0.5-2.5) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/43\">",
"       43",
"      </a>",
"      ]. There were no statistically significant differences between treatment groups in the rates of any cerebrovascular events or cardiovascular events, either during active treatment or after tamoxifen was stopped.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factor V Leiden and prothrombin mutations were not associated with thrombosis in the BCPT [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/44\">",
"     44",
"    </a>",
"    ] or IBIS-I [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/45\">",
"     45",
"    </a>",
"    ] trials involving the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for the prevention of breast cancer. However, in a case-control study from the CALGB, among women taking adjuvant tamoxifen for early stage breast cancer, those who had a thromboembolic event (TE) were nearly five times more likely to carry a factor V Leiden mutation than those who did not have a TE [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/46\">",
"     46",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    A retrospective analysis of DNA from 220 subjects in the Marshfield Clinic Personalized Medicine Research Project found an association between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    -associated thromboembolic events and single nucleotide polymorphisms of the estrogen receptor 1 genotype, although this did not reach the level of statistical significance (hazard ratio 3.5; 95% CI 0.97-12) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possibility that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    may be associated with an increased incidence of arterial thromboembolism (ie, stroke) was raised in two NSABP randomized trials: P-1 and NSABP B-24, a trial of tamoxifen for intraductal breast cancer. However, the available data are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the EBCTCG overview analysis of approximately 15,000 women randomly assigned to receive or not receive five years of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , there was a trend toward increased stroke-related mortality that did not reach the level of statistical significance (54 versus 29 deaths, p = 0.07) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      use was not associated with higher stroke risk in a retrospective nested case control study of 11,045 women enrolled in a large HMO in the Los Angeles area who were diagnosed with breast cancer between 1980 and 2000 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/47\">",
"       47",
"      </a>",
"      ]. When 179 who met the criteria for stroke were compared with 358 age and year of diagnosis-matched controls who had breast cancer but not stroke, there was no association between tamoxifen and stroke risk.",
"     </li>",
"     <li>",
"      In a systematic review of randomized controlled trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      use for breast cancer management and prevention published since 1980, the frequency of ischemic stroke during a mean follow-up period of 4.9 years was 0.71 percent with tamoxifen versus 0.39 percent for controls [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/48\">",
"       48",
"      </a>",
"      ]. It was concluded that, although the absolute risk of stroke was small, women with breast cancer who were treated with tamoxifen had an increased risk for ischemic stroke (odds ratio 1.82, 95% CI 1.4-2.4) or any stroke (odds ratio 1.40, 95% CI 1.1-1.7).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, the increased risks of pulmonary embolus and stroke may be partially offset by a decreased risk of ischemic heart disease in women receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . In the most recent overview analysis of randomized trials of adjuvant tamoxifen from the EBCTCG, the non-significant excess of stroke deaths (three extra per 1000 women during the first 15 years) in women treated with tamoxifen was balanced by a non-significant shortfall in cardiac deaths (three fewer per 1000 women during the first 15 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, there was little net effect of tamoxifen on overall vascular mortality. This beneficial effect may be due to the favorable effect of tamoxifen on lipid profiles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41576?source=see_link&amp;anchor=H9#H9\">",
"     \"Managing the side effects of tamoxifen\", section on 'Coronary heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential mechanisms for the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    procoagulant effect have not been identified. Tamoxifen is an antiestrogen that has weak estrogenic effects which may contribute to its prothrombotic activity. A number of studies have evaluated measurements of hemostasis in patients taking tamoxifen. The results have been conflicting and no major changes have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. Some reports have found modest reductions in antithrombin and protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], while a prospective double-blind study was unable to find consistent tamoxifen-induced changes in protein S or protein C activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aromatase inhibitors are being used as adjuvant hormonal treatment as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . In a systematic review and meta-analysis of seven trials, the use of aromatase inhibitors, as compared to the use of tamoxifen, was associated with a significantly lower incidence of venous thrombosis (1.6 versus 2.8 percent, respectively, OR 0.55; 95% CI 0.46-0.64) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second-line hormonal therapy for patients with advanced breast cancer who fail",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    includes the aromatase inhibitor formestane and the progestational agent megestrol. In a phase III prospective randomized crossover trial, the two drugs showed similar antineoplastic activity but the incidence of deep vein thrombosis was significantly higher with megestrol than formestane (5 in 81 patients versus zero in 90 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prophylactic anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a prospective, double blind study, for example, 311 patients with stage IV breast cancer received either placebo or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (1 mg PO daily for six weeks, adjusted to maintain an INR of 1.3 to 1.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/54\">",
"     54",
"    </a>",
"    ]. Treatment was continued until one week after the end of chemotherapy, which lasted approximately six months. There were seven thromboembolic events in the placebo group and one in the warfarin group (4.4 versus 0.7 percent), a relative risk reduction of 85 percent. Major bleeding occurred in three patients, two of whom received placebo. However, the chemotherapeutic regimens were those in use in the early 1990s and are different from those commonly employed today.",
"   </p>",
"   <p>",
"    In a separate study, the effect of low-intensity",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    on markers of hypercoagulation was evaluated in a randomized trial of 32 patients with metastatic breast cancer who were undergoing chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/55\">",
"     55",
"    </a>",
"    ]. Before therapy, markers of clotting activation were increased in both groups, consistent with the presence of a hypercoagulable state. After starting chemotherapy, markers were progressively lower in the group receiving warfarin prophylaxis. These differences became statistically significant after the fourth course of chemotherapy. Deep vein thrombosis occurred in two of the 16 patients receiving placebo and in none of the 16 patients receiving very-low-dose warfarin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT OF TESTICULAR CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major cardiovascular issues that have been studied in connection with treatment for testicular cancer include hypertension, dyslipidemia, early atherosclerosis and coronary artery disease, Raynaud phenomenon, and thromboembolic events. These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\", section on 'Cardiovascular'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16\">",
"     'Miscellaneous agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     THROMBOTIC MICROANGIOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic microangiopathies have been associated with a number of cancer chemotherapeutic agents. This primarily occurs with one of four regimens:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ; and the use of radiation and high dose chemotherapy prior to hematopoietic cell transplantation (HCT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H22#H22\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Chemotherapy agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The syndrome more closely resembles the hemolytic-uremic syndrome (HUS) than thrombotic thrombocytopenic purpura (TTP) and usually develops within weeks to months after exposure to the drug. Detection may be delayed because chemotherapy can produce thrombocytopenia due to bone marrow depression and renal disease, thereby masking the presence of HUS. Affected patients typically present with slowly progressive renal failure, new or exacerbated hypertension, and a relatively bland urine sediment, often occurring in the absence of clinically apparent tumor.",
"   </p>",
"   <p>",
"    Drug-related endothelial injury is presumed to be the initiating event. It has been proposed that von Willebrand factor (VWF) multimers derived from damaged or stimulated endothelial cells may be involved in the pathogenesis of intravascular platelet clumping. However, there are conflicting data on the role of VWF multimers in patients with drug-induced thrombotic microangiopathies. In one study, VWF multimeric patterns were normal during episodes of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C-induced microangiopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/56\">",
"     56",
"    </a>",
"    ]. However, another report using a superior technique for detection of multimers found abnormalities in VWF in five of six patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/57\">",
"     57",
"    </a>",
"    ]. The sixth patient had a threefold elevation in the levels of VWF antigen.",
"   </p>",
"   <p>",
"    Thrombotic microangiopathy confined to the kidney has been described in association with the use of inhibitors of vascular endothelial growth factor (VEGF) in cancer patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H16#H16\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Drugs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H34#H34\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'VEGF pathway inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other drugs that can be used in patients with malignancy can be associated with thromboembolic events. These are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Estrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;High doses of estrogens increase the plasma concentrations of clotting factors and the risk of thrombotic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/58\">",
"     58",
"    </a>",
"    ]. Estrogenic prothrombotic effects are believed to be responsible for the dose-related cardiovascular complications of the estrogen analogue diethylstilbestrol (DES) in the treatment of prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/59\">",
"     59",
"    </a>",
"    ]. In comparison, the lower doses used for hormone replacement therapy or oral contraception are associated with only a small increase in thrombotic risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link&amp;anchor=H18#H18\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Venous thromboembolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H22#H22\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Cardiovascular disease and diabetes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1353?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial hormone therapy for metastatic prostate cancer\", section on 'Treatment options'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial thromboembolic complications have been associated with use of the angiogenesis inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ; data on venous thromboembolic disease are mixed. The risk of thrombosis and other vascular events (eg, hypertension) with this agent is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link&amp;anchor=H291526420#H291526420\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Bevacizumab and aflibercept'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Antiangiogenic tyrosine kinase inhibitors (TKIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    are orally active multitargeted inhibitors of several tyrosine kinases, including vascular endothelial growth factor (VEGF). Similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , they have been associated with the development of hypertension and arterial thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link&amp;anchor=H291526542#H291526542\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'VEGF receptor TKIs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Fluorouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac toxicity occurs in 1.6 to 2.3 percent of patients treated with 5-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/60\">",
"     60",
"    </a>",
"    ], and myocardial ischemia and stroke occur in up to 10 percent of patients who receive continuous infusions of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/61\">",
"     61",
"    </a>",
"    ]. Induction of coronary spasm is the presumed mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Thalidomide analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis has been noted in a significant percentage of patients with multiple myeloma treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/33/33303?source=see_link\">",
"     pomalidomide",
"    </a>",
"    most often in combination with other agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ). This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=see_link\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have found an increased incidence of thromboembolism in patients with a variety of malignancies treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -containing regimens. While most studies demonstrate an increased risk of VTE, the risk of arterial events is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/62-73\">",
"     62-73",
"    </a>",
"    ]. This question was addressed in two large meta-analyses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis evaluated the incidence of VTE in 8216 cancer patients enrolled in 38 randomized controlled trials comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based regimens with non-cisplatin regimens (either using other platinum drugs or no platinum drugs) for treatment of various solid tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/74\">",
"       74",
"      </a>",
"      ]. This analysis found an overall increase in the incidence of VTE in patients taking cisplatin-containing regimens compared to those receiving non-cisplatin regimens (2.9 versus 1.7 percent; relative risk 1.67; 95% CI 1.25-2.23).",
"     </li>",
"     <li>",
"      A second meta-analysis of the same 38 trials did not find an increase in the incidence of arterial thrombosis in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/75\">",
"       75",
"      </a>",
"      ]. Patients receiving cisplatin-containing regimens had 34 arterial events (0.8 percent; 12 myocardial infarctions [MI], 17 cerebrovascular accidents [CVA], five others) and patients receiving non-cisplatin regimens had 21 events (0.5 percent; 10 MI, 11 CVA).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is associated with a small absolute increase in the risk of VTE, but it does not appear to affect the risk of arterial thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19999147\">",
"    <span class=\"h2\">",
"     Epidermal growth factor receptor inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermal growth factor receptor (EGFR) inhibitors approved for use in patients with malignant disease include the monoclonal antibodies",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    and the orally active tyrosine kinase inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    . The risk of venous and arterial thromboembolic events with these agents was explored in a meta-analysis of 13 randomized clinical trials involving 7073 patients. Results included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/75\">",
"     75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk for development of venous thromboembolic events was significantly increased (RR 1.32; 95% CI 1.07-1.63). On subgroup analysis only the monoclonal antibodies",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      were associated with an increased risk of venous thromboembolism (RR 1.34; 95% CI 1.07-1.68).",
"     </li>",
"     <li>",
"      The risk for development of arterial thromboembolic events was not significantly increased (RR 1.34; 95% CI 0.94-1.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other chemotherapy combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other combinations with potential increased risk of thrombosis or vascular disease include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       Dacarbazine",
"      </a>",
"      , alone or in combination with other drugs, has been associated with the Budd-Chiari syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/54/35685?source=see_link\">",
"       Thioguanine",
"      </a>",
"      and daunomycin, with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , has been associated with veno-occlusive disease of the liver in patients with acute myeloid leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/76,77\">",
"       76,77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       Irinotecan",
"      </a>",
"      with infusional 5-FU plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      (FOLFIRI) has been associated with a higher incidence of VTE than these drugs given on an intermittent schedule in patients with metastatic colorectal cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?6/36/6730/abstract/78\">",
"       78",
"      </a>",
"      ]; however, it is unclear how much of this increase in VTE was due to central catheter-related factors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link&amp;anchor=H5#H5\">",
"       \"Catheter-induced upper extremity venous thrombosis\", section on 'Epidemiology and risk factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4598771\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer is often associated with a state of hypercoagulability, as evidenced by the complications of venous as well as arterial thromboembolic phenomena. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"       \"Hypercoagulable disorders associated with malignancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The hypercoagulable state associated with malignancy can be aggravated by a number of factors, such as surgery, the use of indwelling catheters for the delivery of chemotherapy, and the chemotherapeutic agents themselves. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The chemotherapeutic agents most commonly associated with thrombosis and vascular disease include L-asparaginase,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , and estrogens.",
"     </li>",
"     <li>",
"      The prevention and treatment of venous thromboembolism in patients with cancer are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H10#H10\">",
"       \"Hypercoagulable disorders associated with malignancy\", section on 'Prevention of VTE'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19367?source=see_link\">",
"       \"Treatment of venous thromboembolism in patients with malignancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/1\">",
"      Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004; 164:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/2\">",
"      Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/3\">",
"      Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013; 119:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/4\">",
"      Priest JR, Ramsay NK, Latchaw RE, et al. Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer 1980; 46:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/5\">",
"      Priest JR, Ramsay NK, Steinherz PG, et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 1982; 100:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/6\">",
"      Steinherz PG, Miller LP, Ghavimi F, et al. Dural sinus thrombosis in children with acute lymphoblastic leukemia. JAMA 1981; 246:2837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/7\">",
"      Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol 2007; 138:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/8\">",
"      Qureshi A, Mitchell C, Richards S, et al. Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe. Br J Haematol 2010; 149:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/9\">",
"      Bezeaud A, Drouet L, Leverger G, et al. Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors. J Pediatr 1986; 108:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/10\">",
"      Buchanan GR, Holtkamp CA. Reduced antithrombin III levels during L-asparaginase therapy. Med Pediatr Oncol 1980; 8:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/11\">",
"      Conard J, Horellou MH, Van Dreden P, et al. Decrease in protein C in L-asparaginase-treated patients. Br J Haematol 1985; 59:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/12\">",
"      Gugliotta L, D'Angelo A, Mattioli Belmonte M, et al. Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo. Br J Haematol 1990; 74:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/13\">",
"      Mazzucconi MG, Gugliotta L, Leone G, et al. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study. Blood Coagul Fibrinolysis 1994; 5:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/14\">",
"      Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003; 90:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/15\">",
"      Pui CH, Chesney CM, Bergum PW, et al. Lack of pathogenetic role of proteins C and S in thrombosis associated with asparaginase-prednisone-vincristine therapy for leukaemia. Br J Haematol 1986; 64:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/16\">",
"      Pui CH, Jackson CW, Chesney CM, Abildgaard CF. Involvement of von Willebrand factor in thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. Am J Hematol 1987; 25:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/17\">",
"      Carlsson H, Stockelberg D, Tengborn L, et al. Effects of Erwinia-asparaginase on the coagulation system. Eur J Haematol 1995; 55:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/18\">",
"      Caine GJ, Stonelake PS, Rea D, Lip GY. Coagulopathic complications in breast cancer. Cancer 2003; 98:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/19\">",
"      Clahsen PC, van de Velde CJ, Julien JP, et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 1994; 12:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/20\">",
"      Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 1981; 65:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/21\">",
"      Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/22\">",
"      Goodnough LT, Saito H, Manni A, et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984; 54:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/23\">",
"      Wall JG, Weiss RB, Norton L, et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study. Am J Med 1989; 87:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/24\">",
"      Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/25\">",
"      Rogers, JS II, Murgo, AJ, Fontana, JA, et al. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988; 6:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/26\">",
"      Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 1989; 63:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/27\">",
"      Swystun LL, Mukherjee S, Liaw PC. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost 2011; 9:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/28\">",
"      Kirwan CC, McDowell G, McCollum CN, et al. Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer 2008; 99:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/29\">",
"      von Tempelhoff GF, Dietrich M, Hommel G, Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol 1996; 14:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/30\">",
"      Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011; 103:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/31\">",
"      Hernandez RK, S&oslash;rensen HT, Pedersen L, et al. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 2009; 115:4442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/32\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/33\">",
"      Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993; 85:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/34\">",
"      McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 1995; 311:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/35\">",
"      Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996; 14:2731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/36\">",
"      Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998; 45:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/37\">",
"      Fogarty PF, Rick ME, Swain SM. Tamoxifen and thrombosis: Current clinical observations and guidelines. Principles and Practice of Oncology Updates 2002; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/38\">",
"      Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/39\">",
"      McCaskill-Stevens W, Wilson J, Bryant J, et al. Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen. J Natl Cancer Inst 2004; 96:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/40\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/41\">",
"      Onitilo AA, McCarty CA, Wilke RA, et al. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat 2009; 115:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/42\">",
"      Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/43\">",
"      Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/44\">",
"      Abramson N, Costantino JP, Garber JE, et al. Effect of Factor V Leiden and prothrombin G20210--&gt;A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst 2006; 98:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/45\">",
"      Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 2003; 21:3588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/46\">",
"      Garber JE, Halabi S, Tolaney SM, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst 2010; 102:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/47\">",
"      Geiger AM, Fischberg GM, Chen W, Bernstein L. Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004; 96:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/48\">",
"      Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology 2004; 63:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/49\">",
"      Mannucci PM, Bettega D, Chantarangkul V, et al. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 1996; 156:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/50\">",
"      Pemberton KD, Melissari E, Kakkar VV. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis 1993; 4:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/51\">",
"      Jordan VC, Fritz NF, Tormey DC. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res 1987; 47:4517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/52\">",
"      Mamby CC, Love RR, Feyzi JM. Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women. Breast Cancer Res Treat 1994; 30:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/53\">",
"      Th&uuml;rlimann B, Castiglione M, Hsu-Schmitz SF, et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer 1997; 33:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/54\">",
"      Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/55\">",
"      Falanga A, Levine MN, Consonni R, et al. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial. Thromb Haemost 1998; 79:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/56\">",
"      Monteagudo J, Pereira A, Roig S, et al. Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in mitomycin C-related hemolytic-uremic syndrome. Am J Hematol 1990; 33:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/57\">",
"      Charba D, Moake JL, Harris MA, Hester JP. Abnormalities of von Willebrand factor multimers in drug-associated thrombotic microangiopathies. Am J Hematol 1993; 42:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/58\">",
"      Baird DT, Glasier AF. Hormonal contraception. N Engl J Med 1993; 328:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/59\">",
"      Blackard CE. The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review. Cancer Chemother Rep 1975; 59:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/60\">",
"      Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994; 28:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/61\">",
"      Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 1993; 71:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/62\">",
"      Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011; 29:3466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/63\">",
"      Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990; 17:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/64\">",
"      Doll DC, List AF, Greco FA, et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986; 105:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/65\">",
"      Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 1998; 160:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/66\">",
"      Numico G, Garrone O, Dongiovanni V, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005; 103:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/67\">",
"      Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 1985; 56:2765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/68\">",
"      Hansen SW, Olsen N, Rossing N, R&oslash;rth M. Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Ann Oncol 1990; 1:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/69\">",
"      Berger CC, Bokemeyer C, Schneider M, et al. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 1995; 31A:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/70\">",
"      Reiser M, Bruns C, Hartmann P, et al. Raynaud's phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi's sarcoma. Eur J Clin Microbiol Infect Dis 1998; 17:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/71\">",
"      Hladunewich M, Sawka C, Fam A, Franssen E. Raynaud's phenomenon and digital gangrene as a consequence of treatment for Kaposi's sarcoma. J Rheumatol 1997; 24:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/72\">",
"      Starling N, Rao S, Cunningham D, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009; 27:3786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/73\">",
"      Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/74\">",
"      Seng S, Liu Z, Chiu SK, et al. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol 2012; 30:4416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/75\">",
"      Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 2012; 23:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/76\">",
"      D'Cruz CA, Wimmer RS, Harcke HT, et al. Veno-occlusive disease of the liver in children following chemotherapy for acute myelocytic leukemia. Cancer 1983; 52:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/77\">",
"      Gill RA, Onstad GR, Cardamone JM, et al. Hepatic veno-occlusive disease caused by 6-thioguanine. Ann Intern Med 1982; 96:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/36/6730/abstract/78\">",
"      Mandal&agrave; M, Barni S, Floriani I, et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. Eur J Cancer 2009; 45:65.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1356 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-113.53.254.124-6AF1D2BAE3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6730=[""].join("\n");
var outline_f6_36_6730=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4598771\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      L-ASPARAGINASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antithrombin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      von Willebrand factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT OF BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tamoxifen and raloxifene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prophylactic anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT OF TESTICULAR CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      THROMBOTIC MICROANGIOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MISCELLANEOUS AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Estrogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Antiangiogenic tyrosine kinase inhibitors (TKIs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Fluorouracil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Thalidomide analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19999147\">",
"      Epidermal growth factor receptor inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other chemotherapy combinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4598771\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=related_link\">",
"      Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1353?source=related_link\">",
"      Initial hormone therapy for metastatic prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41576?source=related_link\">",
"      Managing the side effects of tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=related_link\">",
"      Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=related_link\">",
"      Pathogenesis of the hypercoagulable state associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19367?source=related_link\">",
"      Treatment of venous thromboembolism in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_36_6731="Mortality of gastrointestinal-cutaneous fistulae";
var content_f6_36_6731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mortality of gastrointestinal-cutaneous fistulae",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1946-1959",
"       </td>",
"       <td>",
"        45 percent (138 patients - MGH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1960-1970",
"       </td>",
"       <td>",
"        15 percent (119 patients - MGH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1970-1975",
"       </td>",
"       <td>",
"        19 percent (145 patients - MGH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1982-1991",
"       </td>",
"       <td>",
"        20 percent (79 patients - UH)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fischer JE, Evenson AR. Gastrointestinal-cutaneous fistulae. In: Mastery of Surgery, Fischer JE (Ed), Lippincott Williams &amp; Wilkins 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6731=[""].join("\n");
var outline_f6_36_6731=null;
var title_f6_36_6732="Syncope causes dangerous";
var content_f6_36_6732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major life threatening causes of syncope",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Arrhythmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Long QT syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brugada syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bradycardia: Mobitz type II or 3rd degree heart block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Significant sinus pause  &gt;3 seconds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute coronary syndrome, myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Structural Abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Valvular heart disease: aortic stenosis, mitral stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiomyopathy (ischemic, dilated, hypertrophic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial myxoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiac tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aortic dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Significant hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma with significant blood loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tissue rupture: aortic aneurysm, spleen, ovarian cyst, ectopic pregnancy, retroperitoneal hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Saddle embolus resulting in outflow tract obstruction or severe hypoxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Subarachnoid hemorrhage",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6732=[""].join("\n");
var outline_f6_36_6732=null;
var title_f6_36_6733="Age related incidence of epilepsy";
var content_f6_36_6733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Age-related incidence of epilepsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 266px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hauser, WA, Annegers, JF, Kurland, LT. The incidence of epilepsy and unprovoked seizures in Rochester, Minnesota, 1935-1984. Epilepsia 1993; 34:453.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6733=[""].join("\n");
var outline_f6_36_6733=null;
var title_f6_36_6734="ACEI vs Ca blocker in CRF";
var content_f6_36_6734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACE inhibitor and calcium blocker therapy protect against progressive glomerulosclerosis in rats by different mechanisms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 239px; background-image: url(data:image/gif;base64,R0lGODlhcAHvANUAAP///yBzOf8AAAAzmYCAgBA5HH8AAAAZTEBAQMDAwL+/vz8/P39/f/Dw8NDQ0ODg4KCgoAAAADAwMCAgIHBwcJCQkFBQUGBgYLCwsM/Pz+/v75+fn9/f33+ZzI+5nP8/Pz9msv9/fxAQEC8vL29vb19fX1iWa1eWaj8AAB8fHwAMJo+PjwgcDk9PT6+vrw8PD78AAJ+y2P+fnwAmcqvKtMfczW+Mxf9vb6zLtb/M5YKwkP+/vwAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABwAe8AAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrk8NCrKztLW2t7i5uru8vb64Ga/CXgkvC8fIycrLzM3Oz9DR0tPLIwjD2FoJC68K19ngVdvd3+HmUOOu3ufsTumt6+3ySe9JNx/4+fr7+zKN8fMCEqmH5IOAgwgTKlQY4l85gQIJHjG4sOLChowAQgwo0QhFiyAFYFykcaO8jkU+hqw4UlFJk+xQElG5kqFDmBy5LaFZE2HL/zocNkh5iTOczCE8e4pUwoDBkAUKjmwQGiUDiSUKdEIhWjTbUSFJe/4s0vRp1AwcVqzQAKBECQUaOMgNxoHBWgBpGVDdMEIBBwAK9A4JzEDrE65dh30FELbmWCJlhUAFsKCFixJOjzGoO2IEiQwLXPAFIFoBZgAMUjBQsKGFAhJXV7gmYdgJ4sSvFjde+XhIZMpRJ2dF7RR1CSGYZfUFkGFFCW7DAaRwISuC9L/Rtz6s0wACAQxDHhCo0GCI9wS42+hWepFpceDwh0eOvABzUw4lLK+ArjNC07LWAVZbE7e9UUEFCSBAAAANTIBBBd8QcEECEqCXnhrrsZdQb0JscP+cEC/8JRw38xV3mhAaBDhcdClEBQBbKWA3IBMFxpEgABhcIMQE5UnwAAAQUHAhhjOmpOGGS9RXWHEjAqZaBpFpMAJmI2SQH23caPACAy5kkAJsIwDAFwMtFKlEjXBICAABCwKAAHoB3jgkGhkeudQSGfg1RAZsaRAMXlHJRUSebAHG558awCWELENwcOhQ29nhAI9rtvkmAHE+lACbnLJp4ZxZ1Hkkh4Sg2cakDghRgaWpiiBEAhYM1CmbCoKqjZlI2XkQqYOYugaqQzggAYOuAmABeBRUsASbV2w667PQfmqOqBryKoivaiAwAQLcCkGBBBJAIISw3JanBLNWEKD/wgHstuvuu+yq0OY51LJnbSDYGoJuFQQcMMC/AAcs8L8HzDstrmDpeidJkUKyLxX9DixxwAW3U69S9wKSbyEPTxHxxBNXHBPCAMgQwskop6yyyjvcVEnHUnwM8sAi00vyKBsTAnMUMs9MscFG3SxKzoPsDEXPPhMMNDiL4dzwI0Y/gXTSNR/MhA0gZK311lxzHYPLlETtxNQ+Vx00EyAkPXEHYE8idhNkgzyDCgpCa7e0pCyWttoDs53R0468zUTcIbNQwOGIJ654ASwsLYrefPfdtiSCL+tv5AcUEMDmnHfueQAFOB4K5JEH7DfDllR+7uV8Z/7565yHjgrppf97/7pLgCvibK3psq6267C/LvsptNd+exQarPCeEUGpQfQfu4sute9Uax7858ObUnzpxxehgH+SBRfcCi4kseKM2W3xfCCqJ0G4xMBf33n2pWwfefdEZDUCW5PxyUEECghGYKgCmKZkiS5BYUCfELiBzQihLneJwvoA0T4kvI9m1pNf7KT3CfvxDX+DWUAD4QOV7+mlNa+JzWz4g5oRuGAFYZLPCDawH+aEZjQSzB0jKniECwosfhoEHQc94UG1gXBR3NjfZCYToOlU5zoCimJkqiSf4lgnOQpYjnZSN8TBUa9sGQwi/fJGsr3VbgBHjGIDlxiVAPnnP5hCohSZJAsSWf+RMvZx4BZf1kXLlQ6IGhzjKIqYtDRGpzPii6N0XAQjGc0RRImyoxCu+J5CHUaHYnhAAhLwIzLw0Ag+pFgYA9nHTRDSZ4bUyQYACJ8AeQlMYhoBmViYmiU9Mo5SotKfLvmrCUiAWxKYQKrE8MkihBJggJSfIB9XxjPaTgl+Ggxb+ASY/LkIL4+KZlP09CIELmpPisrhGiwwzHHFipildN8XZ5bM6y1zdM10Zhq78JswTJAKCDCXEBqAySsUkwjHJNgolZnOTJxyZvPkgqDGcM8pYGACFGATBRw0hn8OIaADaGfw3gmKg4Isofjq5xce4B0CQKCT6PTnOkGmUdhxtIP/8TwjSDUm0jYQoJwPsAACdAQAcuVzWQXt4UpDNlB3BvUSHl3b5MzggPIkYAIRsIA+gyWBCHxKmEQ4FgCSBVSV/rGoGz2qJZIqsZn+oaFS+IYEUlUBIR3hUjgi56eKBauu9u6rQdzg7EgWgw749a+ADWxgc7DUMlzgR+V4GlwJIAEKTLQ8mZLVrHjHr6HCD6wuFWslmja0mnKBQnVtQESRsNg2cTWyQ3BWpygLMctiMK+beykRhRYKtEoBVhGIgAjc+lYLQYCnXPURkHhrQc1e1LU/xKzwjDsJztbWs2loAIUqkKoGhOuhP5IQaO1aWbzCVradWAwNPEDe8pr3vOet/0Fhf2UE8bBJXAw6EErPMzjmrgm5ooStEPfKhBPot3MeWG+2KmpfjLZ0ufxdgn//u7kA/20NEOCWhLuV0rtiTrnYs28kFrNgBjsYdWrgJ4I2KacwWFQIBsaw58DLCQ4zuMECHgMEyrlVAnv1wvplsSlJ1uH/fhh3XLxx61Q8Pw1DwsUv/nEibLuHE9/Xu3nVsSaQ7GEl1OU/13RPFJpXTyow+Qm5DXNuoRuzAuMXmUTWK/F4/OIAKNl7fZHFX5jQZSZweXleJvMWypEA+JrYzFAWo5EfQWUfn6k2sFlAi2K5gCoRBwAkGMEx2AKbFqQgGDQswWeuUmdItWFYQ9Dz0f8AjePvDtoRhdbvm/NnjGMIRYSkacGLhOACWZelUCRYAWWEkkXUTCdPkrzCl6FwAQps0gLE/YKTU5zjUzci1bBddQiL0KQMlEnSj3bBMVQDnzhGpopYGDYsIIQAZdnYwkNudoKV0GNVH5raURnOCwRoRy+xpSyT0dKjb2kFcT9Bkz2dqrJJnW5TrzsJ7Y72u4nQpHlrgDbEsTcHFpAZoTDgON8Odr9FnQUITMBVGEj2FqIn5N+lObbOZgS08yptIYAGGUL5DHOuApoWbOAqUxFTfVbw6jIpUExUsQrQw81xLAzrG0VXAsnRbXJ1r7m/bW55FyZDBn834egAyOm5u1v/6iinfBErD6LUuSDzqifdChGVAAbUvvXWBpqUB0dCwlkeYzKQGzxt99iZBep07bE5yXUXg58bgPc/l7x6fa/f36v8YDY85OzcdXvXBR33I8xd7IH/ggMQIAIJT+DrxiR40w1OPEzqwASoT73qV796HDwb8lKQ7oQ2SWMwLHvvGT35fkufG9jz4fZvJ+jsfE+JEqsBAiIIM/F7KHrEk157y5eE8dMgAX4CqfC2bz4YE5+36G/Y+064BtKbIF2UZj0BAmf+4bf//PqBn9DvZ8KwLnCgcxaBnxYSFgEQ4Na1E2AC5qd+TOd8Xjc7nTdhCJiACriADNiADviAEBiBDvhL/6fSAA1gAVJlBJsnAhZiLg0QIAjAVkMEfJMHd6cgXSSWgiq4gizYgi74gjAYgzI4gy9Ye2ngHThig0IAV+FRLKjlPtrHTronZbbSChRwARPQUzxlBDwoBBZgbj8IAKrFKayld8FnVEU4D1jnJqQlLRewhFE4hbQShCw1hKCXhZuAdQmwhEXAg19IBCEIAKsSeVZYgsKHhuwQYRCFVUUgHhNwAeJSASLAKT/ifwBIhzGDeweWYXjYDg7AJgG4TySWKppEYuaiSekHSmRIVNzXiNjQhHmXiFcYVp5oDiZ1BiRYcAVYiuBAAQfIf6HIM4pohqwIDg6QgjrIBak4eqtYi//DMHjYN3DrJ4Sd6Ius8HixeDSzWIzGiAob6HlneFGbeFnM2IymIHuT6EnT+FrtZ42suIsESHne2AqwImEi1wXgyH69OI6q4CDZWGGSZTfPggDL2I30II/yiDdsIIb4yCn6iCH9eDfuEJDP8o9zYH9isHQAhQIG0JAO+ZAQiQL1uI7nwpAQeZEPiQLReDQWiZEYqZFp0pEeeZEgCTeGszgoeTiNowcUAAHvSAxjCEoGwB4GMJHiODgzSZMbKTU52RMwgAJ1Q5AEYJD+1JNKYQClRAC0mAcUMGHnqItLQwBGuRI1OYqZNTZTSZU7iZU0uS7w8pXxAnpSeSRIOTZLGQr/MDOWR2mTJoiTGlKWaZKVIFGVmCOWchkScDk4Z3kHt/iS2SeTNMmWd+iWOhkHatkTdNk6dkmWSbmXdtCU3AJRoXiYNZGYvHiTy3KXFpGXbkCZVKmIi/mWjVmNdfCIk6mZC2GZ4diWmSmahomaCqGaZROahQk3jpkH1gePFwWbCSGbxGiPFsSbvbmVcCOcB+GbLEWbRzmawDkHkKktO5mWxikAyMmJzQmYtfkGnomXoKls03mczEmRpemXf2lM01md1Hid5umacRmYf6SciBmemPkJ0umedoiFxcme2nme3ekF26mVZkmamVCfa2mVCJaf2dmZ/Pme3smYAaqeAxqV/wt6n6SIoMv5mvapmA2qn8tym3RQTg0QiUcQYVrFIBdQhQIIUBOqivPpPt/JmTa1okkzN0FJkES5nhx6Lh46B8i4BBAgVQ9wiPRnLH5WXNiJmIKJn4R5oe1ZoK1zkim5OCtpoUyqlwLaBn7IKW+4BBVwTmsFAJSSI4j4n5uZpBW6pPGJoU56max5Lt9JnfLZpnOQpWxCHkzATxDlVmE4jxKaoWw6mK2ZoDHqp+rYosHpoLZ5pYCAAVLlcT+yp5PVp2v6p0oaqFWqoIT6m+J5qDnqPjsqB+XILU8JhxbCLGHKhim6m5mqqYbaQy9KnGj6mRR6lVSapokKoW/gjrQ3OP9SZV3oMaQWUKSpimIyupqA6qadugZkWhHomVyKuiZvCqOe+qxsgJBOACEl2gAn2kUEiqQGyoi1CqBN6q0sKqecKqjTiqtu0JLk6Z+SSq7leqwumqxqsKypuXeLuGJJGa1xKq908JywqJvEuqpl+Kz2mpqwaqmVia+fiqPoakENG6FHurDfqq9c+bD1Wqysaq6uiqhWqq5toK3XAAHB6K4TK6uzeqCxKq77SbDpuakdS6+gFLFvgAAQMCxaJ7DQ6rIv26ony7KYOqmFyrE/C7Q6Sq1rIH47eJo8y40wW7RzmbDIKrQb668xi7Ezi7RqUH3X0FZMS7VVW6lTe6mDCrb/1vm0Dku26Yq2cDApIgAumQiVUMusZkqrK4uXUjuvZtuzRJu2tvqxbGsjN7oF3UqxKQuudxu1agqvxiq2eou1xkSzbkBOqmJuhue33FmxRXaxaqusGluwIHuwCPuggesGPXq5Ktq0zhq6r7q4hkupZ6qwf9uhWkt94WGtJou5c1m3Kiu7RssGoosQzZpfrKshP1mj+IgAktsGHkcArji44hCTulummqtmibuZeXuur9u4sTu2iOmVYPkuKrC8pwKJYaCQqrq3fGu1c8us2Xu12zu07Du91BuvjksHoKizwXucvIu4vou3rouysGu3/7u7h2uxeXCKZlC4AjzAveu9/5X5vu0bmwxrsC9awSDLBq5ojl/LuNxLwBD8u56rumhmwW+JwaV7KrjYwfErv/cLvxEcwJlrv937uB4ctjVcBwDXVCzcwB/8wDYcw03AjzbKuS0Muim8v/x7wJubBx4HcqOqBQw8wzQMwkEswj0EpVGqOFN6vffKxNZbwPXrwP5rB1sYf5Uywb3ZvwjsxaN7q8WrvqubxBcMxiinB1iXs6ibvjeMw1asvUIMuHRMwnwXx3JMvCmswYy1diWLju96xEjss/TrvqQ7yIdcwobcx2cryXFwd9qoxsLLxk3sxrHZr/ObupdcyJacyrlXu2cQYRcQt7mLypq8yX1Ly7N7tP8mzMr5OspiTLd2vHt2AFoEgLtMECTj8ks/dS6P7MMunMMwjMVZu8u17LSczMfVPMfXDLwWAmpP8FDfoFVcxcygvMTBrGNKDKeVvM07y8vLm87Di8mJnAZDubRPsHkY8A10ZcwA1cxUTMZt/MtvLMjsrMTxrMoFXcdVDMRyQABiNmZ3yiNyAqmr5c8GfM77KrOR+1/o/Lm2fMrYDMnr+8KE8IQJUAFfStFUaNFjDNC+HMIADMerLNLWfMsh7cyRbNOAUFJIKC7ChczkPMkUXL13HK4xTdA63c7ZjMgJfcIYDX8oNiEVMqYe/dEkLdSlvM5JbdAo3NSE3MoZDAgkZR7/9UzVXw3WMx3ItEvNNK3NW63QLh3G9MnSwPzURq24Mu3VSy3Per3XCJ3UfFTO1CnKcn3FR73WmYzTVg3Ngj3Ydo2WdP3Fjy3QWZ3Xb/3VvVzYgKzYI83YmjDFF73QZWzYeI3UID2w7szWbc3UgB02kT3Ukw3TpY3Yaf3Pz/zH0WzbfszQnADaLf3Do73Zh63Lia3bOX3aSu3XaM3OgY3VoUzUwkzZw6nVyM3VsU3av73bwd3br73G0N3RGg1Quhfdsl3XcV3UpOzdoh3Qcy3YB/3X1d26lh3fmP3OcA3c7O0Jvm3e503e2E3J833VuMzZNU3f9e3KDtPdz33dwj3b/8Rd26GN3y/935Ld30R4ZNI74MZ93AJ+08O9thCe3Rzu2Rq+4Z2N25iAvqit3Mt92ZAr3hyd0ald3CZe4B1+Cftd4RYu453bQ+MN3jMe4iK+2Cj+2Qpuzus94Q2OvdR948lN4G5t4EHO3K7t3oSN3tJ9EMcrlMob40YM5awt5cqd2Vje3s6N5Dv+5XgJvuHbLuPr5XfN37fN24393mTu352Q47Cd5Jqd20N+4kVe4n9u4yTu4RE+59u9CXqu3nxe5hTO6BKu5H4u59qd30tO6SMe6Jiw6Ave6Hg+6TqO6Il+5o7t6UA+5a3tNkde6qbO46vN130N5rAu5q8O307e3P+CjumZTuekbuc/7uqybuuFvuJjTr5V3utX/ulWHszKjuwMDuqhXumSruir/t4tTus1HuXYfujS3ud13tWpHgibIqxAuOzPbu793ey5Hu27Purrzu5EzuuHAFoX0EecjuaR7uiXvuf5ru/QDumiPu2kzur9fuGA0JJZ581B/e4AH/De7uyeru6GruuA7u4TT/GErumFAFcBYtasfO1Obt0Rf+q1DvLD/uTBbvIaTwgcbwT8yC3zKJIj2ZAowOZtHi9avMUqibzyiAAyP/M1f/PuogI5r/OMw/N24/MzH5E23+ZEb/SJwwJIDy1Kv/QZ2fTh+/RQv/PRkggWYCHFEo//VDj1Qln2Zk+QMH/2ar/2AZn2bP/2cE8rZB/3dN+PKDoIXsuocCPB6cL3fV80fs8vga8F/IQAX1pfguBkwDv4HsP4ZUbtie/4PCP5owb4kM8+lC81mT82m7/3l09BnY/4kW/5Uwa9w2z6pz8Im6T6qM+Orv/6sB/7sj/7n/AAqwIB5YGCmxSiu6oFtm9S5eEAUVwFFJCLTvAAIloFuk8Ev4/7Q4ABbGL8U9D8wT/8VSD8RXizGHDSSfhUhLh/EqLwVaD93C+F3pe/UAAB5G4F3v8t5UH+FZCEbjIh+dz6Pqp25T99I4fGqQAEj0kDUCQmEMUigVCUJJRR6VQqJBoB/0hAg4AgHDEXhAODuEgb4gvRYUFUAAhoG4FZPgiPhxhSLNezoP7sqAqptAAo8oaUiCrOGg0lp6witbi8wMTIzKQqHoogHAAgzEC1IEAf+la7RC0sQAG61iZtb3FzdXd5iyoophKeEkaZtiZke32BpbQumgjOuh4cRPos+pQs4DAchBwa4OQeJB4a5AAivIQSGrAdhlZnCeAb5JWLEC8qfqcA8Qv1a5bk2SxpCKhZA4Atyr4iIlZZaJBgQpYk6LRQbDfhy6NETcoAFDmS5EhjcRAkocikD4EJCEQQAngypcokIpTgPBlhSRMlFyxgACWwiJwKXro04QnAQZIssURUgP8y70HUqQBXXpDAxWfNOFdLziua0iIAnA/FpusZBR6pMxamjtGC0WZRKFpEMCGwNGxfv39DWYjCE9HaNyMhCFZCOAlfnjvXRoFwQUSCk3ajJdAMaikiLXgkJDEG2ik+YcQCDwbg0G9i1Vocp1162S7cr3bn3q17G7ZmzYCBBxc5IZvawmIbTACrjPjiskGfyo6cr4giikVGyaF4ZRRfEUQIfALV4HGe8XyVHQfQvAhhZPlGkWRvPAn0BIIhp1VSqiKAfsmfs6OUsni7CA6mhEtQQVz2qAmY406CJz58GkzpwSSaSqkYn2bzaYnQEAAvNMHQgSA0CezgCwMJJFiDHAShJGgpjxOLS6+0IipEgJkVU4qlpBwvZKqmDdubLqds0mDRjoxeEoNAurawgEXFFqzSyiuxzFLLLbns0ssvwQxTzDHJLNPMM9FMU8012WzTzTfhjFPOOems08478cxTzz357NPPPwENVNBBCS3U0EMRTVTRRRlt1NFHIY1U0kkprdTSSzHNVNNNOe3U009BDVXUUUkt1dRTUU1V1VVZbVXMIAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Beneficial effect of antihypertensive therapy with the calcium channel blocker nifedipine and the angiotensin-converting enzyme inhibitor enalapril in rats with subtotal nephrectomy. At eight weeks, both drugs lowered the blood pressure to an equivalent degree and were associated with better maintenance of the glomerular filtration rate (GFR) and a lesser degree of glomerulosclerosis than untreated rats. However, the mechanism of protection appeared to be different: enalapril lowered the glomerular capillary pressure (PGC), while nifedipine minimized glomerular hypertrophy as manifested by a reduction in glomerular volume.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Dworkin LD, Burstein JA, Parker M, et al. Kidney Int 1993; 43:808.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6734=[""].join("\n");
var outline_f6_36_6734=null;
var title_f6_36_6735="Arm and hand atrophy in ALS";
var content_f6_36_6735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/NEURO/53274/alsaratr_conv.mp4?title=Arm+and+hand+atrophy+in+ALS\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arm and intrinsic hand muscle atrophy in a patient with amyotrophic lateral sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arm and intrinsic hand muscle atrophy with a \"claw hand\" appearance is noted. Fasciculations causing intermittent movement of the left fingers are apparent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nestor Galvez-Jimenez, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_36_6735=[""].join("\n");
var outline_f6_36_6735=null;
